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Background: Antimicrobial resistance is a major challenge for patient safety 
worldwide, as a growing number of infections become difficult to treat and the 
advances made in modern medicine are threatened. Overuse and misuse of antibiotics 
accelerates the development of resistance. Optimizing treatment for the patients of 
today, while conserving effective antibiotics for future patients is therefore of great 
importance. Antimicrobial stewardship is a strategy and coherent set of actions which 
promote responsible use of antibiotics.  
 
Objectives: The main aim of this project was to contribute to the knowledge needed 
to implement antibiotic stewardship in Norwegian hospitals through a) determining 
the impact of audit with feedback and academic detailing with local target setting on 
antibiotic prescribing practice b) understanding how patient outcomes are associated 
with adherence to clinical guidelins on initiation of antibiotic treatment and c) 
determining whether targets for antimicrobial stewardship interventions can be 
identified through  analysing the antibiotic prescribing process in Norwegian 
hospitals with patient-level data.  
 
Materials and methods: All three substudies were part of a combined multicentre 
study, performed within the specialties of pulmonary medicine, infectious diseases 
and gastroenterology at three hospitals in Western Norway. Study 1 included 1802 
patients and was a randomised, controlled intervention study, assessing the impact of 
academic detailing, audit with feedback and local target setting on adherence to 
antibiotic guidelines and changes in locally defined targets. Study 2 and 3 were 
observational cohort studies, including 1756 patients and 1235 patients, respectively.  
 
Results: In study 1 there was an absolute increase in adherence to guidelines of 6% 
across all intervention wards (p=0.04). When analysed per specialty, pulmonary 
intervention wards had a 14% absolute increase in adherence (p=0.003), while other 
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intervention wards had no observed impact of interventions on adherence. 
Intervention wards receiving audit with feedback decreased the use of broad-
spectrum antibiotics (level and trend). Local target setting at one of the pulmonary 
wards led to a 30% increase in targeted prescribing behaviour (p<0.001). In study 2, 
guideline-adherent prescribing was associated with lower in-hospital (OR=0.46, 
p=0.003) and 30-day mortality (OR=0.48, p=0.001). There was also a trend towards 
shorter length of stay (-0.47 days) when guidelines were followed. Analysing the 
process of antibiotic prescribing in hospitals (study 3) identified 5 main targets for 
antimicrobial stewardship interventions: a) adherence to guidelines, b) prescribing in 
the emergency room, c) prescribing for patients admitted from other institution, d) 
understanding cultural and contextual drivers of antibiotic prescribing and e) duration 
of treatment.  
 
Conclusions: The impact of antimicrobial stewardship interventions on prescribing 
practice was dependent both on the context (e.g. specialty) in which interventions 
were implemented and how they were implemented. Pulmonary intervention wards 
increased adherence to guidelines with both audit with feedback and academic 
detailing, and additional impact was seen when locally defined targets were 
identified. We have shown that adherence to Norwegian antibiotic guidelines was 
associated with favourable patient outcomes across a range of common infectious 
diseases, both in terms of in-hospital- and 30-day mortality.  Targets for antimicrobial 
stewardship interventions in hospitals were identified through analysis of patient-
level, antibiotic prescribing data from admission to discharge and WHO AWaRe 
categories provided a useful system for analysing antibiotic regimens throughout the 
hospital stay. Although the studies were performed in Norwegian hospitals, we 
believe that the methods and findings will be applicable in other clinical settings 
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1.  INTRODUCTION 
Antimicrobial resistance (AMR) has become a global crisis, as microbes, in particular 
bacteria, have become increasingly resistant to antibiotics 1. Today, an estimated 
700 000 deaths are caused by infections with antibiotic-resistant microbes globally, of 
which 33 000 deaths are in the European Union and the European Economic Area 1-3. 
The most alarming predictions of the implications of AMR are heavily debated, but 
suggests that by 2050, the number of deaths could increase to 10 million per year 
globally, unless prompt action is taken 3, 4. Development of AMR is fueled by 
decades of overuse and misuse of antibiotics in multiple sectors and environmental 
pollution 5-8.  
AMR is not a new phenomenon. Although recognized by the communities of 
microbiologists and infectious disease physicians at an early stage, raising awareness 
of this important challenge has taken time.  WHO published its first global strategy 
on AMR in 2001 9. However, it was more recent, among others with the publication 
of the O’Neill report in 2014 and the Global Action Plan on AMR in 2015, that AMR 
was globally recognized as a public health threat, which, if not reversed, could put an 
end to modern medicine and cause millions of deaths worldwide 3, 10. It was also 
recognized that joint efforts across all sectors involved in antibiotic production, 
policymaking, prescribing, handling and use were necessary to curb AMR 6, 11. This 
prompted more coordinated actions on AMR from governments, professional bodies, 
scientists and healthcare workers, such as national action plans on AMR, surveillance 
of AMR and antibiotic use, research and development on new antibiotics and policies 
to optimize antibiotic use both at community- and hospital levels 3, 8, 10, 12-21.  
Norway has had strict policies for antibiotic use and low rates of AMR, which has 
made it possible to continue the use of narrow-spectrum antibiotics for a wide range 
of diagnoses 22-24. Outbreaks caused by resistant bacteria in hospitals and long-term 
care fascilities (LTCF) and patients dying from multidrug resistant (MDR) bacterial 
infections are however increasing across the world, and Norway is no longer an 
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exception 2, 3, 25-27. The studies undertaken as part of this PhD-project aimed to 
increase the understanding of how antibiotics are used in Norwegian hospital settings, 
how patient outcomes are associated with antibiotic prescribing and how prescribing 
practices can be improved. 
1.1 ANTIMICROBIALS 
Antimicrobials are substances that inhibit the growth of – or kill microorganisms, 
such as bacteria, viruses, funghi and parasites and are therefore divided into 
antibacterials, antivirals, antifungals and antiparasitic drugs 28. This thesis will focus 
solely on the use of antibacterials and the term antibiotics will be used.  
Antibiotics are one of the greatest achievements in the field of medicine, saving 
countless lives since their introduction into clinical practice 29. Between 1937 and 
1943, maternal mortality in the United States declined by 24-36%, mortality due to 
pneumonia declined by 17-32% and scarlet fever mortality declined by 52-65%, due 
to sulphonamides 29, 30. With the introduction of penicillin, mortality associated with 
pneumococcal pneumonia and bacteraemia declined from 20-40% to 5% and 50-80% 
to 18-20%, respectively 31. 
The term antibiotics are now used both for synthetically produced chemotherapeutic 
agents with antimicrobial effects (e.g. sulphonamides and fluoroquinolones) and the 
antibiotics which originates from microorganisms (e.g. penicillin). The arsenic-based 
chemical known as Salvarsan, was the first antibacterial agent used in the modern 
antibiotic era, synthesized by Erlich in 1907 and used to treat syphilis 29, 32. Next in 
line was the Sulphonamides, which were the first antibiotics produced in large scale 
and put into practice in 1935, followed by penicillin in 1941 29.  
Even though antibiotics are perceived as miracle drugs, the benefit of prescribing 
antibiotics should always outweigh the risks. Misuse and overuse of antibiotics 
increases antimicrobial resistance in the society, and antibiotics also have potential 
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adverse effects for the individual patient. Allergies and diarrhea are common when a 
patient is treated with antibiotics and some antibiotics, especially clindamycin, 
cephalosporins and quinolones, are especially prone to cause a serious, secondary 
bowl infection with toxin-producing Clostridium difficile (C.diff) 33. In addition to 
eradicating pathogenic bacteria, taking antibiotics changes the commensal flora, 
including the useful bacteria in our microbiome. The impact on the commensal flora 
are increased with the use of broad spectrum antibiotics, killing more bacterial 
species than the narrow-spectrum antibiotics. Bacteria help us digest food, produce 
vitamins and protects us from overgrowth of pathogenic bacteria and funghi, 
including multidrug resistant bacteria. The way the microbiota is changed and the 
impact this has on human health is not fully understood, but changes in the 
microbiotia have been linked to overveight, diabetes, cancer and inflammatory bowl 
disease 34. How the routes of administration of antibiotics affect the gut microbiome 
is also an area that needs future research 34.  
1.2 ANTIMICROBIAL RESISTANCE 
AMR is defined as “the ability of a microorganism (e.g., a bacterium, a virus, or a 
parasite, such as the malaria parasite) to resist the action of an antimicrobial agent” 28. 
AMR is seen in both bacteria, funghi, viruses and parasites, but will in this thesis be 
discussed in relation to bacterial resistance only.  
AMR was described already in the 1945 Nobel Lecture from the famous discoverer 
of penicillin, Alexander Fleming, and resistant strains of Staphylococcus aureus were 
reported in patients receiving penicillin therapy as early as 1942 35, 36. Bacteria can be 
naturally resistant to some antibiotics, a trait known as intrinsic or inherited resistance 
28. Examples are gram-negative bacteria being resistant to glycopeptideantibiotics 
(e.g. vancomycin) because the outer membrane of gram-negative bacteria renders the 
targeted peptidoglycan cell wall inaccessible to the drug 37. Resistance can also be 
developed through mutation in the bacterial genes and be passed on to the next 
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generation of bacteria (vertical transmission) or bacterial resistance genes can be 
passed on from one bacterial species to another (horizontial transmission) 28.  
Important mechanisms of antibiotic resistance are 1) antibiotic inactivation, 2) target 
alterations and 3) decreased access to the target site 38. Some bacteria can produce 
beta-lactamases, enzymes that inactivates beta-lactam antibiotics by openening the 
beta-lactam ring in their chemical structure 37. Beta-lactamases inactivates penicillins 
and first generation cephalosporins, while extended spectrum beta-lactamases 
(ESBL) inactivates both penicillins, higher generation cephalosporins and 
monobactams 37.  Carbapenemases are beta-lactamases that also inactivates 
carbapenems, an important class of last resort antibiotics 37. ESBLs and 
carbapenemases are found in gram-negative bacteria, such as Enterobacteriacae, 
Klebsiella pneumoniae and Escherichia coli 37. To protect beta-lactam antibiotics 
from being inactivated by beta-lactamases, enzyme-inhibitors have been developed 
and added to some antibiotic formulations, such as piperacillin-tazobactam, 
amoxicillin-clavulanic acid and ceftazidim-avibaktam.  The most predominant 
mechanism of resistance to beta-lactam antibiotics in gram-positive bacteria is 
alteration of the target molecule, penicillin-binding-protein (PBP), as seen in 
methicillin resistant Staphylococcus aureus (MRSA) 37. Resistance can also be 
manifested by a change in antibiotic permeability of the outer membrane, a 
mechanism escpecially seen in gram-negative bacteria, which renders the antibiotic 
ineffective because it does not reach the target site. Decreased permeability can for 
example be seen in some of the beta-lactam antibiotics (e.g. aztreonam, ceftazidim 
and imipenem) 39. Another mechanism of resistance is upregulation of efflux pumps, 
where antibiotics are pumped out of the cell where they should exert their effect. 
Both upregulation of efflux pumps and alteration of target molecules are seen with 
tetracyclins and fluoroquinolones 37. 
When bacteria are exposed to antibiotics, sensitive bacteria will die, while resistant 
bacteria will survive and prosper, a process which may result in the selection of 
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bacteria resistant to antibiotics. This can happen during treatment of infectious 
diseases with antibiotics, both in hospital and community settings. Resistant bacteria 
can further spread among humans, animals and in the environment, and resistance 
genes can be transferred to other bacteria. Even though bacteria may have developed 
or acquired resistance elsewhere, resistant bacteria are often detected in hospital 
settings through the processes of diagnosing infectious diseases or screening the 
patient during admission. Resistant strains spreading in the hospital environment is a 
fear for healthcare workers, patients and managers.  
A few decades have passed since Flemings Nobel Lecture and AMR rates have 
steadily increased to become a serious threat to the effective treatment of infectious 
diseases 8.  
1.3 HOW TO COMBAT AMR 
AMR can only be contained and fought if action is taken across all relevant areas and 
sectors 1 (Figure 1). 
1.3.1 Governance 
The WHO Action Plan on AMR in 2015, called for action in the individual member 
states. National action plans agains AMR have since been developed by more than 
100 countries across the world 1. Resistant bacteria know no boundaries and AMR 
can not be solved within an individual country alone. Both global and national 
governance are needed and the work must be prioritized across human- and animal 
health, agriculture and the environment, so that the necessary human, structural and 
financial resources are made available in all sectors with joint efforts to maximise the 
effect of actions taken 40-43.   
1.3.2 Vaccination 
Vaccination is important in combating AMR in multiple ways. Available vaccines 
reduce the prevalence of both bacterial and viral infections.  As viral infections are 
often inappropriately treated with antibiotics and also give rise to secondary bacterial 
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infections, reducing both bacterial and viral infections will contribute to a reduction 
in the need for antibiotics 10, 44. Effective, worldwide vaccination programmes are 
therefore an important contribution to combating AMR. 
1.3.3 Infection prevention and control (IPC) 
Infection prevention and control (IPC) are complementary to antimicrobial 
stewardship and both are needed to help curb resistance 45. Effective infection 
prevention and control measures lower the need for antibiotic treatment through 
reducing the spread of infectious agents, which in turn prevents bacterial infections. 
As a consequence, less antibiotic treatment is needed 46. IPC is escpecially 
challenging in low- and middle-income countries where even basic measures like 
access to clean water in healthcare institutions can be lacking 46. Securing access to 
efficient hand hygiene, environmental cleaning, disinfection, sterilisation and 
education of staff in IPC are some of the core elements needed for IPC in healthcare 
facilities 46. 
1.3.4 Access to antibiotics  
Globally, there is also a lack of access to antibiotics, and it is estimated that more 
people die from not having access to antibiotics than from infections with multidrug 
(MDR) resistant microorganisms 31. In countries where over-the-counter use of 
antibiotics is commonplace, substandard and falsified medicines are more prevalent 
and adds to other challenges of inappropriate use, such as unsuitable choice of drug, 
dose and duration of treatment 47.  
Availability of antibiotics is an increasing challenge also in high-income countries, 
and Norway has experienced shortages of both broad-spectrum- and old, narrow-
spectrum antibiotics the last few years, leaving us with fewer treatment options 48. 
Old antibiotics may give limited return of investment for pharmaceutical companies 
and are therefore not marketed. Physicians may then be forced to prescribe 
unnecessary broad-spectrum antibiotics when the preferred narrow-spectrum 
antibiotics are unavailable 49.  
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There needs to be a balance between policies, laws and regulations that maintain 
control of the use of these valuable medicines and yet securing that antibiotics are 
available to those who need them. This requires a sustainable system where 
healthcare workers are able to make good and qualified decisions on prescribing and 
dispensing and have both old and new antibiotics at hand 47, 50. 
1.3.5 Development of new antibiotics 
Although some new antibiotics substances have been introduced in clinical practice 
in recent years, new classes of antibiotics have not been discovered since the 1980s  
51.  The discovery void and the dry pipelines related to antibiotics from the 
pharmaceutical industry, represents a tremendous challenge as we currently cannot 
count on new antibiotics to save us from the threat of AMR 52-54. The business models 
for the industry rely on large sales volumes to justify development costs. As 
antibiotics have become a resource which we must spare in order to contain AMR, 
we need new business models (i.e. public-private partnerships) and incentives to 
ensure continued discovery and development of antibiotics 50, 55-57. 
1.3.6 Alternative treatment options 
With increasing rates of AMR, alternative treatment options for infections with 
multidrug resistant bacteria are investigated. An old technique, which was mostly 
abandoned with the introduction of antibiotics, uses bacteriophage therapy to kill 
resistant bacteria. This technique has been in continous use in Eastern Europe, but is 
now re-discovered also in the western world and recently saved the life of a 15-year 
old girl in England 58, 59.  Use of immune-based therapies or treatments attacking host 
targets rather than microbial targets, such as blocking the effect of bacterial toxins or 
modifying host inflammation response are being studied 60. Another option includes 
new individualized cocktails of antibiotics, drawing on collateral antibiotic 
susceptibility, where resistance to one antibiotic agent increases susceptibility to 
other antibiotics 61. Innovative, alternative treatment options should be investigated as 
part of the fight against AMR.  
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1.3.7 The “One health” perspective 
Substantial amounts of antibiotics are used outside human medicine, to promote 
animal growth and prevent infections in livestock, for treatment of companion 
animals and in agriculture. In the United States, 80% of all antibiotics sold are used in 
animals, while in Norway, 89% of antibiotics sold are for human use 62, 63. AMR arise 
from all antibiotic use, regardless of sector and a “One health” perspective, 
combining efforts and resources from human, animal, food and environmental health 
is therefore needed to tackle and contain resistance 10, 11, 31.  
1.3.8 Reducing environmental pollution 
Antibiotic waste in sewer systems and as wastewater of antibiotic production must be 
addressed, as this can affect development of resistance in environmental bacteria 6, 64, 
65. Vast amounts of antibiotics, with concentrations exceeding “safe” levels by up to 
300 times, are found in rivers across the world, and in effluents from a wastewater 
treatment plant in India, high levels of broad-spectrum antibiotics was detected 66, 67. 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.3.9 Public awareness 
Raising public awareness regarding the use of antibiotics and the challenges of 
resistance, may relieve the perceived pressure on physicians to prescribe antibiotics 
or decrease self medication with antibiotics 68-70. An increased understanding of 
which infections are self-limiting, when antibiotics may be useful and when they do 
more harm then good is necessary and a state of mind in all levels of society as 
described in the catchphrase “Antibiotics – only when needed.” Travelling to 
countries with high prevalence of antibiotic resistance poses a risk for being 
colonized or even infected with multidrug-resistant bacteria 71, 72. Both the public and 
healthcare personell need to be aware to be sure that this information is conveyed or 
asked for if a patient is seeking help for an infection upon return from travel. Taking 
part in ordinary vaccination programmes in their home country and securing 
additional vaccines before travel to other countries with different panorama of 
infectious diseases are important contributions from the public in the fight against 
AMR.  
1.3.10 Surveillance, microbiology and rapid diagnostics 
Guidelines for antibiotic use are built on an understanding of the aetiology of 
infections and levels of resistance in causative bacteria. Resistance data are supplied 
through surveillance systems at microbiology labs or prevalence studies performed in 
a local context to inform policy makers and guideline developers 23, 73. Identifying the 
cause of an infection or eliminating infection as a potential diagnosis are important 
contributions to optimising antibiotic use in healthcare. However, communication 
barriers between microbiology labs and clinical units and challenges related to long 
turn-around-times and lack of availability of microbiological test results, have limited 
their use 74-77. Fortunately, rapid diagnostics are evolving, reducing turn-around-times 
and improving access to valuable test results, supporting the prescriber in making 
wise choices regarding prescribing (or no prescribing) of antibiotics and improving 
patient outcome 77-80. Although the term is heavily debated, the involvement of 
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laboratories in the fight against AMR is currently being referred to as diagnostic 
stewardship 79, 81. Access to microbiological diagnostics and surveillance data are 
important in all countries to inform day-to-day clinical practice and the development 
of guidelines for prudent antibiotic use.  
1.3.11 Optimising the use of existing antibiotics 
One of the keys to preserving antibiotics and curbing the selection of resistant 
bacteria is to optimise the use of existing antibiotics. The catch phrase “The more we 
use them, the more we lose them” is an easily conveyed message, describing the 
relationship between antibiotic use and AMR. Antibiotics should be prescribed only 
when needed, with an optimal selection of antibiotics in the correct doses and 
administration forms, administered at the right time and interval and for the shortest 
possible duration. Clinical guidelines, informing prescribers about prudent and 
appropriate antibiotic use in the local context are one of the keys to optimising the 
use of antibiotics.  
1.4 CHALLENGES OF ANTIBIOTIC PRESCRIBING AND USE 
Antibiotics are used for the treatment of bacterial infections and surgical prophylaxis, 
a practice which has drastically reduced mortality from infectious diseases 29. 
Furthermore, the great advances in modern medicine the last 70 years, including 
prostetic surgery, cancer therapy and transplant medicine would not have been 
possible without effective antibiotics to prevent and handle complications resulting 
from these procedures 10. Increasing AMR rates are making it more and more difficult 
to find effective antibiotic options to treat these complications, which ultimately may 
jeopardize these achievements because the procedures become too risky to perform.  
In 2012, 20 to 55% of patients in acute care hospitals across Europe were prescribed 
antibiotics 82. It is estimated that in up to 50% of cases where antibiotics are 
prescribed in hospitals and up to 75% of prescriptions in long-term care facilities, 
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antibiotics are inappropriate (not needed or suboptimal) 14, 15, 83. One main challenge 
that needs to be addressed is therefore overuse and misuse of antibiotics. 
Both AMR and antibiotic consumption differs from country to country and also 
within countries and institutions 8, 73, 84-87. Countries with extensive antibiotic use also 
have high levels of AMR 5, 88. The global consumption of antibiotics in human 
medicine increased by 65% between 2000 and 2015 89. Together, Brazil, Russia, 
India, China and South Africa make up 40% of the worlds population but accounted 
for three-quarters of the 36% increase in the period between 2000 and 2010 31. Still, 
there are great challenges related to limited access to antibiotics in low- and middle-
income countries, with more people dying from lack of antibiotics than antibiotic 
resistance 31. In children younger than 5 years, access to antibiotics could potentially 
reduce deaths from community-aquired pneumonia by 75.4%, saving close to 
450 000 lives across 101 countries 31.  
For the individual physician making treatment decisions on behalf of a patient, 
antibiotic prescribing could potentially include an ethical dilemma, weighing 
individual patient risk against societal risk 90.  Maximum coverage in all empirical 
antibiotic treatment regimens with broad-spectrum antibiotics today are expected to 
cause a rapid increase in rates of resistance, leaving antibiotics without effect for 
future patients 91. Balancing this risk can be challenging and guidelines may help by 
incorporating available evidence and risk assessment into recommendations, allowing 
individual physicians to lean on guidelines when making clinical decisions.  
Securing access to antibiotics for those who will benefit from them, but at the same 
time ensuring that antibiotics are used responsibly to minimize AMR are key 
challenges today. AMR can not be resolved in high-income countries alone but needs 
a worldwide engagement and inverventions across all sectors and levels of care 41-43. 
25 
 
1.5 AMR AND ANTIBIOTIC USE IN NORWAY 
Norway is at the lower end of both antibiotic use and levels of resistance, with 
exceptionally low levels of antibiotics used in agriculture and fish farming 23. An 
important contribution to the low levels of antibiotic use in humans was a unique 
regulatory paragraph implemented in Norway between 1938 and 1994, called the 
“need clause.” This paragraph allowed Norway to only register drugs and drug 
formulations which were considered needed in the Norwegian setting, until the 
adaptation to European legislation in the 1990s 22.  This postponed the introduction of 
many antibiotics in Norway and was also crucial in securing that antibiotics are not 
sold over-the-counter, but are for prescription use only 22. In Norway, 82% of 
antibiotics for use in humans are prescribed in primary care, and only 8% of 
antibiotics are used in hospitals 23. This could suggest that antibiotic use in hospitals 
are of limited importance and that all efforts should be placed in securing prudent 
prescribing in primary care.  Norway does however have a limited number of broad-
spectrum antibiotics available for oral treatment, leaving many broad-spectrum 
antibiotics to be used mainly within the hospital setting. Hospitals are a setting where 
frail, sick and immunocompromised patients are gathered in a confined area with 
high antibiotic pressure and extensive use of broad-spectrum antibiotics, and is 
therefore an ideal environment for the selection and spread of antibiotic resistant 
bacteria. Responsible use of antibiotics in the hospital setting is therefore of great 
importance. More advanced antibiotic therapy is increasingly given in long term care 
facilities (LTCF), adding to the rationale of a call for action also in these institutions 
92, 93.  
The link between antibiotic use and AMR is widely acknowledged, but how the 
distribution of antibiotic use in the society is associated with AMR has only just been 
investigated. Studies suggests that to reduce AMR, we gain more by reducing the 
broadly distributed, low-intensity use in a broad population, compared to intense, 
repeated use in single patients 5, 85.  
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Norway has had several policy documents, outlining the threat of AMR, and in 
December 2015,  the National action plan against antibiotic resistance in health 
services followed the National strategy against antibiotic resistance (2015-2020) 13, 
94-96. The national action plan covers measures directed at the public, hospitals and 
primary care, including general practitioners, dentists, emergency wards physicians 
and other primary care healthcare institutions 95. Some of the goals outlined are a 
30% reduction in total antibiotic use, measured from 2012 to 2020 (DDD/1000 
inhabitants/day) and a 30% reduction in the use of a selection of broad-spectrum 
antibiotics in hospitals (DDD/100 bed days) during the same period. In 2018, a 24% 
reduction in the total use of antibiotics had been achieved, while the hospitals had 
reduced broad spectrum antibiotics by 12 % 63. 
1.6 MEASURING ANTIBIOTIC USE 
1.6.1 Defined daily doses 
Consumption of antibiotics is most often measured and monitored by the use of 
antibiotic sales statistics, coupled with activity data. European Contries, including 
Norway, have been collecting data on antibiotic use for many years, but low- and 
middle income countries in particular, struggle with collecting reliable data 23, 84. 
WHO Defined Daily Doses (DDD) is primarily used as the nominator in drug 
statistics. The DDD is defined as “the assumed average maintenance dose per day for 
a drug used for its main indication in adults” 97. In hospitals, the unit of measurement 
is usually DDD/100 hospital bed days or DDD/100 admissions, while primary care 
usually measures DDD/1000 inhabitants per day 23, 84. Sales data can for example be 
made available from pharmacies or wholesalers and be combined with data from 
hospital administrative systems and national registries where such systems are in 
place. DDDs for parental antibiotics used in hospitals are sometimes artificially low 
compared to normal hospital dosing as DDD is a theoretical unit that do not often 
change, while there in hospitals has been a steady increase in dosing over the years.  
To make up for this difference, hospital adjusted DDDs have been proposed 98. It 
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should however be noted that the DDDs for many important antibiotics (e.g. 
ampicillin, meropenem) were increased in the latest WHO ATC/DDD Index update 
in 2019 99. 
1.6.2 WHO AWaRe categories 
In the 20th edition of the Model List of Essential Medicines in 2017, the World 
Health Organization (WHO) grouped antibiotics into access, watch and reserve-
categories (AWaRe) and the list was recently updated 100, 101. Access group antibiotics 
should be widely available, affordable and quality assured. First or second choice 
antibiotics for reviewed clinical syndromes were assigned to this group. Antibiotics in 
the watch group have a higher potential for resistance, are first or second choice 
treatment for only a limited number of indications and should be prioritized as key 
targets of stewardship programmes and monitoring. Reserve group antibiotics are the 
“last resort” options which should be protected and preserved and included as a focal 
point of stewardship programmes to secure available treatment options in life-
threatening infections with multidrug resistant bacteria 100, 102. Although not all 
antibiotics are included in AWaRe, this new categorization of antibiotics is a new 
option for measuring and comparing antibiotic prescribing and use. Antibiotic 
consumption according to AWaRe differs substantially between countries and 
continents. Classified by the WHO Model List of Essential Medicines from 2017, the 
Nordic countries use less than 20% Watch group antibiotics, whereas in  Georgia, 
Jordan and Japan, corresponding figures were 52%,  59% and 76%, respectively 84.  
1.6.3 Quality indicators 
While sales statistics are easily collected, these types of aggregated data do not reveal 
antibiotic prescribing patterns at patient level and do not connect indication for 
treatment with the antibiotics used. It is therefore difficult to use only this kind of 
data to identify challenges in prescribing practices and plan targeted interventions to 
improve prescribing practice. For the purpose of analyzing and enhancing prescribing 
quality, audits are frequently used for data collection. It allows more in-depth 
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knowledge of prescribing practice in relation to indications for antibiotic treatment 
and development of tailored interventions in the local context.  
Quality indicators (QI) for measuring the appropriateness of antibiotic prescribing 
can be helpful in identifying areas with room for improvement 103, 104. The degree of 
adherence to clinical antibiotic guidelines is an often reported QI in studies evaluating 
implementation of antibiotic stewardship interventions in hospitals and ranges from 
43 to 90% adherence with guideline recommendations 105.  
1.7 ANTIMICROBIAL STEWARDSHIP 
1.7.1 What is antimicrobial stewardship? 
The term stewardship was first introduced in relation to antibiotics by McGowan and 
Gerding in 1996 with regards to ensuring optimal antimicrobial use and consideration 
of the long-term effects of antimicrobial selection, dosage and duration of treatment 
on development of resistance when deciding on antimicrobial treatment 106.  
There is no single, global definition of antimicrobial stewardship (AMS), but it has 
most recently been defined by the European Society for Clinical Microbiology and 
Infectious Diseases Study Group for Antimicrobial Stewardship (ESGAP) as a 
strategy, a coherent set of actions which promote using antimicrobials responsibly 107. 
In comparison, the Infectious Diseases Society of America (IDSA) and the Society 
for Healthcare Epidemiology of America (SHEA) and the Pediatric Infectious 
Diseases Society (PIDS) have made a consensus statement, defining antibiotic 
stewardship as “coordinated interventions designed to improve and measure the 
appropriate use of [antibiotic] agents by promoting the selection of the optimal 
[antibiotic] drug regimen including dosing, duration of therapy, and route of 
administration” 108. For the purpose of this thesis, only stewardship related to 
antibiotics will be discussed and the term AMS will refer to antibiotic stewardship.   
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1.7.2 Antimicrobial stewardship programmes in hospitals 
Core elements of antimicrobial stewardship programmes (AMS-programmes) and 
handbooks of AMS have been published by multiple professional bodies like The 
Infectious Disease Society of America (IDSA), The American Centers for Disease 
Control and Prevention (CDC) and the European Society of Clinical Microbiology 
and Infectious Diseases (ESCMID) 14, 21, 108-111. To ensure that AMS-programmes 
have an impact in the hospitals in which they are implemented, these core elements 
should be in place. Structure, process and outcome indicators which can help assess 
and compare the AMS-programmes have also been proposed, both at hospital- and 
national levels 103, 112-115. 
Commitment from senior hospital management leaders towards AMS-programmes is 
a core element to secure credibility and legitimacy to the programme and the 
necessary focus and resources for the stewardship programme, both in terms of 
human recources, but also financing and resources related to information technology 
109, 110. 
Expertise on infection management and laboratory and imaging services with timely 
results should be available. Clinical antibiotic guidelines based on published 
evidence and data on local susceptibility should be available to prescribers, along 
with policies regarding documentation of antibiotic treatment plans and available 
advice from an AMS-team. The AMS-team should include healthcare professionals 
trained in infection management and stewardship, such as physicians, pharmacists 
and nurses 110. Other valuable members are a clinical microbiologist, information 
system specialist, an infection control professional and a hospital epidemiologist 14.  
Another core element is to secure accountability and assign responsibilities in a 
stewardship programme to the hospital management, AMS-committee, AMS team 
and the clinical staff. A healthcare professional should be identified as leader of the 
stewardship team and a physician leader is often beneficial for the implementation of 
the programme 110. Stewardship programmes should take action and implement 
30 
 
interventions aimed at optimising antibiotic use, such as review of antibiotic therapy 
or audit with feedback. Providing clinicans with valuable education on antibiotic 
prescribing and resistance, and providing the AMS-team also with practical training 
in stewardship is recommended 110. The stewardship team should have clearly defined 
roles and responsibilities, incuding monitoring, surveillance and reporting of process 
and outcome measures and quality indicators. This can include monitoring total 
antibiotic use and use of broad-spectrum antibiotics, rates of resistance, degree of 
adherence to guidelines, rate of review of therapy, adherence to interventions or 
agreed goals 108-110. Feeding back this information to clinicians and leaders aids in 
the implementation and sustainability of AMS-programmes. Procedures of 
collaboration with other relevant hospital commitees should also be in place 14, 110.  
ESCMID has developed generic competencies (knowledge, attitudes and skills) in 
antimicrobial prescribing and stewardship which can be used in training for 
independent prescribers, like hospital physicians 116. Specialist antimicrobial 
stewardship knowledge are outlined in a comprehensive overview of knowledge and 
skills required for leaders of antimicrobial stewardship programmes by SHEA and 
partnering societies, and includes the following ten categories 1) general principles of 
antimicrobial stewardship, 2) stewardship interventions, 3) antimicrobials, 4) 
microbiology and diagnostics, 5) common infectious syndromes, 6) measurement and 
analysis, 7) informatics, 8) programme building and leadership, 9) special 
populations and non-acute hospital settings and 10) infection control  117. 
1.7.3 Antibiotic prescribing in hospitals  
Antibiotic prescribing in hospitals is dependent on both culture, context and 
individual behaviour 76, 118-121. A recent study from England shows that medical and 
surgical teams have different perceptions and norms of antibiotic prescribing. 
Medical teams have a higher extent of team perspective with input from other 
professionals, while surgical teams perceive antibiotic decision making as a 
nonsurgical intervention, leaving to a greater extent junior staff or other specialties to 
prescribe antibiotics 118.  In Norwegian hospitals, junior physicians rely on clinical 
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guidelines for antibiotic prescribing and the input from infectious disease-physicians 
(ID-physicians) are perceived as highly valuable 76. In England, hierarchy is more 
pronounced, and the head of the department will influence prescribing policy to a 
great extent 119. The perceived value of - and confidence in clinical guidelines will 
also affect prescribing practice 122. Ownership to guidelines is important in all areas 
of practice, but in infectious diseases, bacterial aetiology of infections and local 
resistance patterns will differ between countries and regions, meaning guidelines 
must be informed by local context 122.  
As antibiotic use and development of AMR is closely linkend, the decision of 
antibiotic prescribing does not only influence the patient of today, but also our future 
patients. Diagnostic uncertainty and a perception of AMR not being an imminent 
threat, are however factors that may cause antibiotics to be prescribed also against 
advice in clinical guidelines 122-125.  Another important factor affecting prescribing 
practice is the fear for a patients wellbeing, leading to prescription of antibiotics “just 
in case” or prescription of more broad spectrum than recommended 125.  When 
attempting to change antibiotic prescribing it is therefore important to take into 
account the balance between the perceived individual patient risk and the societal risk 
if antibiotics are rendered ineffective 90.  
1.7.4 AMS interventions 
To curb and contain resistance, interventions must be applied across all sectors and 
include the public. A new term, drawing on the success of the “carbon footprint” has 
been proposed as a communication tool to make the public aware of the magnitude of 
antibiotic use and how reduction in overuse and misuse of antibiotics worldwide can 
be achieved in all sectors (human, animal and agriculture/industry) 126. The term is 
called “the antibiotic footprint” and the goal is to reduce antibiotic consumption to a 
minimum 126. For the purpose of this thesis, only health system interventions applied 
in the hospital setting will be described in more detail.  
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Health system interventions are divided into four categories and defined by the 
Effective Practice and Organisation of Care (EPOC) as 127:  
1. Delivery arrangements: changes in how, when and where healthcare is organized 
and delivered and who delivers care. This category includes for example the 
subcategory of environment - changes to physical healthcare environment, like 
altering equipment, the subcategory of outreach services and the subcategory of 
health information systems.  
2. Financial arrangements: changes in how funds are collected, insurance schemes, 
how services are purchased and the use of targeted financial incentives or 
disincentives. 
3. Governance arrangements: rules or processes that affect the way in which powers 
are exercised, particularly with regard to authority, accountability, openness, 
participation and coherence. The category includes for example the subcategories of 
prescribing and authority and accountability for quality and practice – exemplified 
by implementation of clinical guidelines.  
4. Implementation strategies: interventions designed to bring about changes in 
healthcare organizations, the behaviour of healthcare professionals or the use of 
health services by healthcare recipients. The subcategories of organisational culture, 
audit and feedback, educational outreach and tailored interventions are included 
here.  
AMS- interventions in hospitals are found mainly in the categories of delivery 
arrangements and implementation strategies and can again be divided into 
environmental restructuring, restrictive and enabling/persuasive interventions 105.  
Environmental restructuring interventions apply changes to the physical 
prerequisites, for example by changing from paper to electronic medical charts, 
introducing new rapid diagnostics, reminders (e.g. posters/pocket cards summarising 
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antibiotic polices) and changing the physical environment where prescribing is 
performed 105.  
Restrictive interventions are defined as “using rules to reduce the opportunity to 
engage in target behaviour (or increase the target behaviour by reducing the 
opportunity to engage in competing behaviours) 105.” Examples of restrictive 
interventions are applying formulary restrictions or pre-approval, automatic stop 
orders or selective reporting of laboratory susceptibilities 105. Restrictive interventions 
are effective in reducing broad-spectrum antibiotic use, but sustained effects are more 
likely if restriction is combined with enabling interventions 105.  
Making it easier for clinicans to access information which is needed for appropriate 
prescribing are known as enablement strategies 21. This could be easy access to 
guidelines, decision support or microbiological test results.  
Interventions aimed at improving knowledge and changing attitudes and beliefs about 
antibiotic prescribing are also called enabling interventions or persuasive 
interventions, and examples are education, audit with feedback and academic 
detailing 21, 105.  Educational meetings or distribution of educational material are 
frequently used in AMS-programmes, but this type of intervention is of limited 
efficiency when used alone 14, 105. Audit with feedback, where a summary of clinical 
performance over a specified period of time is fed back to clinicans, is however a 
more effective intervention 105. Educational outreach are interventions where a trained 
person meets with providers in their practice setting to give information, intending to 
change the providers practice 128. Academic detailing is such an intervention where 
information is given and current practice is discussed 128. Persuasive interventions are 
effective and may be easier to implement in a variety of settings as they are more 
readily accepted by clinicians 21, 129.  
Information technology can also be applied to change behavior, through development 
of applications supporting prudent prescribing, “serious” gaming - educating 
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clinicians and the public - and clinical decision support systems, helping clinicans to 
prescribe, review and discontinue antibiotic treatment appropriately 130-132. 
1.7.5 Outcome of AMS 
AMS-studies often report process indicators of appropriate antibiotic use, like the 
rate of review of antibiotic therapy or change in antibiotic use. Process indicators are 
important in order to evaluate whether interventions are implemented or not. The 
ultimate goals of AMS are however to improve patient outcome, (e.g. morbidity and 
mortality) and lower or contain antibiotic resistance rates. It is often difficult to show 
an effect on resistance rates following individual intervention studies, as the studies 
are normally confined in length of follow-up, resistance rates are influenced by many 
other variables and individual studies lack power to detect these differences 133.  To 
be able to assess cost-effectiveness of stewardship activities, economic outcomes (e.g. 
costs/savings) should also be reported more often 134.  
Qualitative methodology is needed to understand the way stewardship changes 
prescribing behaviour and beliefs and perceptions of antibiotics in institutions and the 
society.  
1.8 BEHAVIOUR CHANGE FRAMEWORKS 
Behaviour change interventions can help close the gap between recommended, 
evidence based clinical practice and actual practice in hospitals. As hospitals differ 
from each other and wards within hospitals differ, taking the specific context into 
consideration can help increase effect of such interventions. Social- and behavioural 
sciences provide different frameworks for behaviour change which can be utilized in 
AMS, such as the COM-B-model and the Theoretical Domains Framework 135. The 
COM-B-model postulates that in order for behaviour to occur or change, a person 
needs to be capable (have knowledge and skills), have the opportunity (physically 
and socially) and have motivation in order for a certain behaviour to occur 135. The 
Theoretical Domains Framework incorporates barriers and enablers which can 
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influence behaviour and can be linked to the COM-B. The domains (e.g. knowledge, 
skill, environmental context, resources, beliefs, goals etc) can be subcategories of the 
three pre-conditions of the COM-B, (Capability, Opportunity and Motivation) 135, 136. 
Flottorp et al have provided a comprehensive checklist which includes 57 potential 
determinants of practice, grouped in seven domains: 1) guideline factors (e.g 
compatibility with current practice and source of recommendations), 2) individual 
health professional factors (e.g. knowledge and skills, agreement with 
recommendations), 3) patient factors (e.g. patient needs and preferences , 4) 
professional interactions (e.g. communication and influence), 5) incentives and 
resources (e.g. information system, assistance for clinicians), 6) capacity for 
organisational change (e.g. capable leadership, relative strength of supporters and 
opponents)  and 7) social, political and legal factors (economic constraints on the 
healthcare budget, payer or funder policies) 137. Frameworks and checklists like these 
can be used both as tools for planning behaviour change interventions and to improve 





2. AIMS AND OBJECTIVES 
The overall aim for this PhD-project was to gain knowledge needed to implement 
antibiotic stewardship in Norwegian hospitals through determining 
 the impact of antibiotic stewardship interventions in a Norwegian hospital 
setting 
 how patient outcome is associated with antibiotic prescribing practice and  
 if analysis of patient-level antibiotic prescribing data throughout hospital 
admission can identify targets for antibiotic stewardship interventions.  
 
Figure 2: Overview of studies and aims: 
 
 
2.1 STUDY I 
Aim 
The aim of this study was to investigate the impact of behaviour change 
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antibiotic prescribing practices in hospitals. The findings of this study are reported in 
paper I.  
 
Objectives 
To investigate to what degree implementing audit with feedback and academic 
detailing with stakeholder involvement and local target setting affects a) adherence to 
national clinical practice guidelines for antibiotic use in hospitals and b) use of broad 
spectrum antibiotics and c) locally set targets, across hospitals in Western Norway.  
2.2 STUDY II 
Aim 
This study aimed to investigate how appropriate, guideline-adherent antibiotic 
prescribing was associated with patient outcomes. The results from this study are 
reported in paper II. 
 
Objectives 
To analyse the association between adherence to national guidelines for antibiotic use 
in hospitals at inititation of treatment, and in-hospital- and 30-day mortality, 
readmission and length of stay (LOS) for inpatients. 
2.3 STUDY III 
Aim 
The aim of the study was to describe and analyse the process of antibiotic prescribing 
from admission to discharge to identify targets for antibiotic stewardship 
interventions. The results from this study are reported in paper III. 
 
Objectives 
a) To describe and analyse the process of initiating, modifying and stopping 
antibiotics throughout the hospital stay.  
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b) To identify factors associated with non-adherence to national guidelines for 
antibiotic use in hospitals. 
c) To explore if WHO AWaRe-categories are useful for analysis of patient-level 
prescription data in hospitals. 
d) To explore if we can identify targets for antibiotic stewardship interventions 
through the knowledge gained from a-c. 
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3. MATERIALS AND METHODS 
3.1 OVERVIEW 
Table 1 gives an overview of included papers, materials and statistical analyses 
applied.  
Table 1: Overview of papers 





The effect of antibiotic 
stewardship interventions 
with stakeholder 
involvement in hospital 





















    
II The association between 
adherence to national 
antibiotic guidelines and 
mortality, readmission and 
length of stay in hospital 
inpatients: Results from a 
Norwegian multicentre, 
observational cohort study. 


















    
III Identifying targets for 
antibiotic stewardship 
interventions through 
analysis of the antibiotic 
prescribing process in 
hospitals - a multicentre 
observational cohort study 
















3.2 STUDY DESIGN 
Study 1 was a randomised, controlled intervention study, where hospitalised patients 
were included prospectively on initiation of antibiotic treatment. Data were gathered 
retrospectively after hospital discharge. Primary outcome measures were adherence to 
the national guideline for antibiotic use in hospitals, change in agreed target areas of 
follow-up from intervention sessions and change in the total activity-adjusted use of 
broad-spectrum antibiotics.  
Study 2 and 3 were both observational cohort studies and used data collected in the 
intervention study. In study 2, primary outcome measures were mortality, 
readmission and length of stay, and outcomes were analysed according to status for 
adherence to guideline on treatment initiation, with adjustment for probable 
confounders.  
In study 3, we focused on the process of antibiotic prescribing. Primary outcome 
measure was the type of antibiotic regimens used throughout the admission, grouped 
by WHO AWaRe categories and adherence to guidelines on initiation of treatment. 
Secondary outcome measures were 1) the patterns of antibiotic prescribing from 
admission to discharge, grouped by diagnoses and 2) non-adherence to guideline. In 
the latter analysis, factors associated with non-adherence were investigated.  
3.3 SETTING 
All three studies were conducted at Haukeland University Hospital, Stavanger 
University Hospital and Haraldsplass Deaconess Hospital within the specialties of 
infectious diseases, pulmonary medicine and gastroenterology. Haukeland University 
Hospital and Stavanger University Hospital are tertiary care hospitals with 1100 and 
600 beds, respectively. Haraldsplass Deaconess Hospital is a not-for-profit, privately 





The participants included in all three studies, were patients receiving antibiotics 
during admission to one of the study wards between February and July of 2014. For 
overview of participants, see Figure 3. Study 1 included 1802 patients, of which 1279 
were included pre-intervention and 523 post-intervention. Pre-intervention, 478 
patients were included in audit with feedback, 451 in academic detailing and 350 in 
the control group. Post-intervention 182 patients were included in audit with 
feedback, 172 in academic detailing and 169 in the control group.  Only the first stay 
of readmitted patients was included.  
Five physicians and two pharmacists working at the included hospitals were part of 
the intervention teams in study 1. All physicians working at the intervention study 
wards were invited to attend the interventions sessions and attendance ranged from an 
estimated 70 to 100% at the study wards. 
Study 2 included adult patients from the cohort of study 1 (N=1756). Patients for 
whom outcome data was unavailable (tourists etc) and/or comorbidity data was not 
possible to retrieve from the hospital administrative system, were excluded.  
In study 3, the cohort consisted of patients from study 2 (N=1235), with diagnoses 
belonging in the groups of lower respiratory tract infections (LRTI), acute 
exacerbations of chronic obstructive pulmonary disease (AECOPD), Sepsis, skin- and 
soft-tissue infections (SSTI) and urinary tract infections (UTI). The groups of post-
intervention patients from intervention wards and patients with diagnoses categorized 
in the groups of gastrointestinal infections (“GI-infections”) and “Other diagnoses” 













3.5 DATA COLLECTION AND HANDLING 
The main data collection for all three studies was manually performed, extracting 
data from electronic medical records by the use of paper case report forms (CRFs). 
Included data were patient demographics, indications for antibiotic treatment, 
antibiotics prescribed, and doses given during admission, antibiotics prescribed upon 
discharge, microbiological test results, patient outcome (mortality, readmission and 
length of stay), estimated glomerular filtration rate on admission and admittance 








 Intervention wards in pre-intervention period and control wards 
 Diagnoses: LRTI, AECOPD, Sepsis, SSTI, UTI 
 
Study 2 
 Adult patients with available comorbidity- and outcome data  
 Diagnoses: LRTI, AECOPD, Sepsis, SSTI, UTI, GI-infections, other infections 
 
Study 1 
 Study wards: Infectious diseases, pulmonary medicine and 
gastroenterology 
 Patients treated with antibiotics during admission 
 Recommendation for empirical choice of antibiotic available in the 
National guideline for antibiotic use in hospitals 





For study 1, additional data regarding the use of broad spectrum antibiotics at ward 
level were extracted from the hospital pharmacies sales statistics and adjusted per 100 
bed days, using data from the hospital administrative system.  
For study 2 and 3, additional data on coded diagnoses present at discharge (ICD-10-
codes) were extracted from the hospital administrative system and used to calculate 
Charlson Comorbidity Index (CCI) 138, 139. 
Data were manually plotted into the statistical software SPSS for Windows, version 
24, with coded variables and later transferred to STATA SE version 15 (Stata 
Statistical Software, College Station, TX, USA). Data validation was performed by 
manually checking plotted data against CRFs upon database completion. Missing 
data were sought in the electronic medical record and CRF and database completed 
when possible.   
3.6 STATISTICAL ANALYSIS 
Statistical analysis was performed using SPSS version 24 and Stata SE version 15 for 
study 1 and Stata SE version 15 for study 2 and 3.  
3.6.1 Paper I 
To assess the effect of the antibiotic stewardship interventions audit with feedback 
and academic detaling, analysis was performed both per intervention group and per 
specialty. Analysis per cluster was originally planned, but due to fewer patients than 
expected in the post-intervention period, this was not performed. Pearsons’ chi-square 
was used to test categorical data and two-sample t-test was used for continuous data. 
By using simple logistic and linear regresson models, we evaluated the group-by-
period interaction term to test whether adherence to guidelines and patient outcome in 
intervention groups and specialties changed differently over time, when compared to 
the control group.  
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Interrupted time series (ITS) analysis was used to assess the level- and trend of 
activity-adjusted broad spectrum antibiotic use, through the method described by the 
Effective Practice and Organisation of Care Group (EPOC group) 140.  A significance 
level of 5% was used for all analyses.  
Sample size 
Sample size calculations performed before initiation of study 1 was based on 
adherence to guidelines. Baseline adherence was unknown, and we therefore used 
two approaches for sample size calculations in the study protocol. For the 
intervention study, a baseline adherence to guidelines of 50% and an improvement in 
adherence to guidelines of 20% following interventions was assumed for each cluster. 
With a power of 80% and significance level of 5%, we needed 93 patients included 
before and after interventions in each cluster. It was proposed in the original study 
protocol that adherence to guidelines in antibiotic prescribing should be 80% or more 
and we therefore did an additional calculation, using a one-sample binomial test for 
proportions. With 80% power and type 1 error of 0.025 (one sided), the smallest 
sample needed to detect a statistically significant difference between adherence of 
70% vs a reference rate of 80%, was 155 patients.  As baseline adherence was 
unknown, we therefore aimed to include at least 155 patients in each cluster before 
and after interventions (Figure 4).  





















Parameters:  = .05, p0 = .8, Cu = .
Binomial test
H0: p = p0  versus  Ha: p  p0




3.6.2 Paper II 
Chi-square test and two-sample t-test were used to analyse differences in patient 
characteristics between the two groups of adherence and non-adherence to guidelines. 
In assessment of the association between adherence to guidelines and patient 
outcomes (mortality, readmission and length of stay), we used univariate and 
multivariate logistic and linear regression. In multivariate regression analysis we 
adjusted for indication for treatment, comorbidity (CCI), age group, admittance from 
institution, sex and seasonality. A Fine and Gray-model was also fitted as a 
sensitivity analysis to analyse length of stay with in-hospital death as competing risk.  
A p-value below 0.05 was considered statistically significant for all analysis.  
3.6.3 Paper III 
In paper III we studied the process of antibiotic prescribing by a) looking at the 
degree of antibiotics prescribed belonging to the different groups in the WHO 
AWaRe categories, b) process measures of antibiotic prescribing and c) factors 
associated with non-adherence to guidelines. Descriptive statistics were used to 
analyse a) and b), while factors associated with non-adherence to guidelines were 
analysed using multiple logistic regression analysis.  
3.7 ETHICS 
This research was conducted in accordance with national and institutional standards 
and the Declaration of Helsinki and approved by the data protection officer 
(2013/9352) and local managers. The regional ethical committee approved the waiver 





4.1 PAPER I: AMS-INTERVENTIONS 
The overall impact of audit with feedback and academic detaling across intervention 
wards was an absolute increase in adherence to antibiotic guidelines from 60% to 
66% (p=0.04). This impact was however not significant when compared with control 
wards (time-by-period interaction). When comparing pulmonary medicine wards with 
control wards, the total impact of interventions was significant, with an increased 
adherence to guidelines of 14% (p=0.034). For the specialties of gastroenterology and 
infectious diseases there was no total impact of interventions. Main results from study 
1 and 2 are given in Figure 5. 
Activity adjusted use of broad-spectrum antibiotics was analysed using interrupted 
time series. For the audit with feedback wards, the trend showed significant decrease 
in the use of broad-spectrum antibiotics and the level of broad-spectrum antibiotic use 
was reduced at both 12 and 18 months post intervention. For the groups of academic 
detailing and control and for intervention wards per speciality, there was no 
significant change in broad-spectrum antibiotic use.  
During the interventions, the physicians at the intervention wards were encouraged to 
set local targets for follow-up. The pulmonary ward at hospital A targeted an increase 
in the use of penicillin 2 mill x 4 for patients with pneumonia and AECOPD and 
managed to increase the use by 30% (p<0.001), following the intervention. The ward 
of gastroenterology at hospital A targeted a reduction in the use of ciprofloxacin and 
this was reduced at all timepoints following the intervention, although not statistically 
significant. The other intervention wards did not identify any targets or did not 
achieve consensus on 1-2 measurable targets.  
Compared with control wards, mortality, readmission and length of stay for 
intervention groups and specialties was not significantly changed during this study.  
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4.2 PAPER II: PATIENT OUTCOME WHEN ADHERING TO 
GUIDELINES 
When investigating the association between adherence to the national antibiotic 
guideline and patient outcomes, we found that both in-hospital and 30-day all cause 
mortality was lower in the adherent group. For 30-day mortality, the adherent group 
had an odds-ratio (OR) of 0.48, p=0.003, while for in-hospital mortality OR=0.46 
with p=0.001. 30-day readmission was not associated with adherence to guidelines, 
but there was a trend towards shorter length of stay for patients (-0.47 days, 95% CI 
(-1.02, 0.07, p= 0.081) for patients treated according to antibiotic guidelines and 
discharged alive. This was supported by competing risk analysis of LOS, where the 
subdistribution hazard ratio for discharge in the adherent group was higher, compared 
to the non-adherent group (SHR=1.17, 95% CI (1.02, 1.34)). 
Figure 5: Main results from study 1 (orange) and study 2 (blue) 
 
Empirical antibiotic
therapy adherent to 
guidelines





















4.3 PAPER III: THE PROCESS OF ANTIBIOTIC PRESCRIBING IN 
HOSPITALS 
A description of the main results from study 3 are given in Table 2, with more details 
given in the following paragraphs.  
4.3.1 WHO AWaRe 
When empirical antibiotic prescribing was according to the national antibiotic 
guideline for antibiotic prescribing in hospitals, 89% of antibiotic regimes were 
classified in the access category of the WHO AWaRe categories, containing 
antibiotics with the least potential of increasing AMR. When empirical prescribing 
was non-adherent, only 49% of antibiotic regimens were in the access category, but 
the proportion av access-group antibiotics increased for the second regimen (61%) 
and for antibiotics prescribed upon discharge (74%).  
4.3.2 Antibiotic prescribing - process measures 
Initiation of treatment 
Antibiotics were most often initiated in the emergency department (83.6%), but this 
varied from 64.8% for patients with UTI to 96.8% for patients with sepsis. 63% of 
patients received empirical treatment according to guidelines on initiation of therapy. 
Initiating therapy at the ward was associated with non-adherence to guidelines with 
an OR= 1.7 and 95% CI (1.24, 2.36).  
When patients were admitted from an institution, they were more likely to receive 
non-adherent empirical treatment (OR=1.44, 95% CI (1.04, 2.0)). Compared to 
hospital A, being admitted to hospital B was beneficial in terms of avoiding non-
adherence to guidelines on initiation of treatment with an OR of 0.63 and 95% CI of 




The majority of patients (61.4%) had their first antibiotic regimen changed during 
admission. For 20.6% of patients, the initial antibiotic regimen was kept throughout 
the admission, but changed at discharge.  
Oral antibiotic therapy was prescribed for 84.5% of patients during the course of 
treatment. For UTI patients, mean day of first oral treatment was 2.7 days 95% CI 
(2.3, 3.1), while patients diagnosed with sepsis had a mean first day of oral treatment 
at 5.1 days 95% CI (4.6, 5.5). 
At discharge 
A minority of patients were considered cured at discharge, with 77.4% of patients 
continuing antibiotics when leaving the hospital. The mean total days of antibiotic 
treatment was 10.6 days across diagnosis and the mean days of in-house and post-
dishcarge therapy did not vary much between the groups of diagnoses. Patients with 
sepsis had the longest duration of in-house therapy, with a mean of 6.6 days. The 
highest number of post-discharge days of therapy (7.1 days) was prescribed to 
patients with SSTI, while 5.8 days were the mean days of post-discharge therapy for 
















































































Through this PhD-project, we aimed to contribute to the knowledge and 
understanding needed for implementing antibiotic stewardship in Norwegian hospital 
settings. The national guideline for antibiotic use in hospitals is a cornerstone in this 
work, constituting evidence based and desired practice.  The research has taken us 
from exploring the effect of tailored AMS-interventions, through investigating how 
adherence to guidelines affect patient outcomes and lastly investigating the antibiotic 
prescribing process from admission to discharge to find factors that are associated 
with non-adherence to guidelines and targets for antibiotic stewardship interventions. 
In the following, methodology and results of the included studies will be discussed, 
highlighting strengths and weaknesses which could impact reliability, internal- and 
external validity and discuss our work in relation to others’.  
5.1 METHODOLOGICAL CONSIDERATIONS 
5.1.1 Internal validity 
Internal validity reflects the confidence that we can place in the findings of a study, 
meaning that the study measured what it intended to measure and the research 
questions could be answered correctly, in a manner free from bias 141, 142.  Some 
factors affecting validity are only applicable to study 1 and are hence only discussed 
in relation to this study. Additional details of strengths and limitations are included in 
the published papers. Internationally recommended checklists have been applied 
when reporting on all three studies, with the use of the extended CONSORT checklist 
for study 1 and the STROBE checklist for study 2 and 3 143-145. 
Selection bias 
Study design and randomization 
Proper study design is vital to secure internal validity of the study. Many studies 
investigating AMS-interventions have been uncontrolled before-after studies, and 
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interventions were often a response to an outbreak 105, 146. These studies are prone to 
bias, often with outcome measures normalising and “regressing to the mean” when 
the outbreak is over 146.  
Study I was a multicentre, cluster randomised, controlled intervention study, 
performed in a “normal” clinical setting with control wards in all hospitals to be able 
to control for random time effects. The clusters were wards within three specialties at 
three different hospitals with limited flow of staff between them. The gold standard of 
intervention research, the randomised controlled trial (RCT), would mean 
randomising individual patients within the wards to control or intervention. Although 
this would make the intervention and control groups more homogenous, it is not 
applicable in this type of study, because it would cause contamination between the 
groups as the same physicians would treat both control- and intervention group 
patients and hence it would be impossible to assess the effect of the interventions. A 
cluster randomised, controlled study is therefore considered a strong and 
recommended design for studies investigating stewardship interventions, reducing 
risk for bias 146. Randomization for study 1 was performed by drawing lots of 
hospitals and intervention groups per specialty. As there were only two hospitals with 
gastroenterology wards, only one intervention and one control group were drawn for 
this specialty. Randomization decreases the likelihood of selection bias when 
allocating interventions to the participating wards.  
Study 2 and 3 were both multicentre, observational cohort studies, mainly utilizing 
data collected during Study 1. Observational cohort studies are considered a weaker 
design than experimental studies, as they are susceptible to selection bias and loss to 
follow-up and used for assessing associations, but not causation. The cohorts of study 
2 and 3 were derived from the intervention study cohort, with prospectively included 
patients and retrospectively collected data to allow for sufficient time to have past 
after discharge to record 30-day mortality and 30-day readmission.  
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Confounding by indication 
Guidelines for antibiotic use should incorporate existing evidence on aethiology of 
infections, treatment options and local resistance patterns in recommendations, 
securing safe treatment for the individual patient with minimal impact on both the 
individual patient’s microbiota and the environment. The main outcome measures in  
Study 1 were adherence to guidelines, use of broad-spectrum antibiotics and change 
in locally targeted prescribing behaviour. Adhering to guidelines could be affected by 
the prescribers’ perception of the balance between the present risk of the individual 
patient and the future risk for the society with increasing AMR if broad-spectrum 
antibiotics are prescribed 122. The prescriber’s trust in guidelines could therefore also 
influence treatment decisions, along with a fear for the patient’s wellbeing 122. At the 
time the intervention study was initiated, the newly released Norwegian antibiotic 
guidelines had been developed with broad involvement from more than 80 physicans 
throughout the country and the trust in the guidelines was perceived to be high.  
Increased severity of infection could still likely fuel a fear for underprescribing, such 
as the use of narrow-spectrum antibiotics or lower doses 122. Severity of infections 
were however not recorded, and it is therefore a possibility that severity of infections 
could have varied pre- and post interventions and also between the specialties, 
introducing selection bias or confounding by indication. Recorded patient 
characteristics were however similar in the pre- and post intervention periods.  
 
This potential bias could also have an effect on the results in study 2, the cohort study 
investigating the effect of adherence to guideline on patient outcome. If the more 
severely ill patients are more likely to receive non-adherent treatment, this could 
affect the association between guideline adherence and mortality, readmission and 
length of stay. The association we found between adherence to guideline and low 
mortality could be overestimated if this assumption is true for our study population.  
We also know that there were more patients admitted from institutions in the non-
adherent group, which is suggestive of more comorbidities, but also that physicians 
consider the risk of resistant pathogens to be higher. The non-adherent group also had 
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more patients with GI-infections, UTIs and “other” infections, and since the case-mix 
was different, this could potentially influence the results. To increase internal 
validity, we adjusted analysis for major confounding factors, such as morbidity 
(through Charlson Comorbidity Index) and admission from other institution, 
indication for treatment, age, sex and seasonality. Although previous studies have 
reported favourable outcomes of adherent prescribing, to the best of our knowledge, 
no such study have been performed in the Norwegian context 134.  
 
Assessment of adherence was for all patients based on the indication for treatment 
given in the patients’ medical notes. The indication was usually a preliminary 
diagnosis given in admission notes and could change as more diagnostic information 
(microbiological test results, x-rays etc.) became available during the hospital stay. 
Even though the diagnosis may have changed during admission, the first indication 
for treatment is still what the physician based the choice of initial empirical antibiotic 
regimen on and it reflects real-life hospital practice, where decisions are based on 
available knowledge at the time. In study 3 we looked at the consistency between 
indication for treatment and infection discharge diagnosis (if present). There was low 
consistency for the group of patients with sepsis compared to other groups. This 
could mean that patients were diagnosed with suspected sepsis, but the diagnosis 
were later modified, but it could also be due to lack in documentation, as the focus of 
infections is often documented at discharge. In study 2, we did a sensitivity analysis 
for 30-day mortality, where we substituted indication for treatment with discharge 
diagnosis in regression analysis. This only changed the estimate to a minor degree for 
the association between adherent treatment and 30-day mortality. 
 
The main data collection was performed by manual data extraction from the patients’ 
electronic medical record. Collection of individual patient data was extremely labour 
intensive, and it was necessary to restrict the data collection period. Performing a 
feasibility study could have been beneficial, especially with regards to assessing time 
for data collection and completeness of data. Originally, we also wanted to include 
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information from radiology and other examinations performed, but this was not 
feasible given the extra time for data extraction and was dropped from the case report 
form at an early stage. Inclusion of more data could however made validation of 
indication for treatment possible.  
 
Detection bias 
When assessing adherence to guideline, a syntax was made in SPSS, connecting 
indication for treatment with antibiotics and combination of antibiotics and assigning 
a status of regarded 1) adherent, first line treatment, 2) alternative treatments and 3) 
other, non-adherent treatments, effectively blinding the assessment of adherence to 
avoid detection bias (systematic differences in outcome assessment). Patients with 
antibiotic allergies or kidney failure were assessed manually to check if alternative 
treatments were to be regarded adherent. This assessment was performed blinded to 
study period, also to avoid introducing detection bias. This schematic way of 
assessing adherence could however potentially have made us miss some cases were 
comorbidity or other individual factors would explain a different choice of therapy.  
 
Data on mortality, readmission and length of stay, were collected from electronic 
medical records. Readmissions were only identified if the patients were readmitted to 
the same hospital they were discharged from, which is a limitation to the study.  
 
Performance bias 
Except from intervention-team physicians, intervention-ward physicians were not 
informed of the study taking place in the pre-intervention phase of study 1. Control-
ward physicians were not aware that the study took place, throughout the study 
period, minimizing bias of change in behaviour due to the fact that ones’ behaviour is 




During data collection of individual patient data, we only recorded antibiotic 
treatment given and not other types of active treatment and care given during 
admission. This could potentially introduce performance bias when looking at 
outcome measures of mortality, readmission and length of stay if there were 
systematic differences in the care provided, other than antibiotics.  
There was no regularly collected data which could be used as a substitute to assess 
adherence to guidelines. Assessing long-term sustainability of interventions was 
therefore difficult and we needed to find a proxy indicator for sustainability of 
intervention. The use of broad-spectrum antibiotics was therefore analysed. This has 
its limitations, because it is difficult to relate this directly to the interventions, but as 
the Norwegian guidelines mostly recommend narrow-spectrum antibiotics in the 
empirical regimen it was considered a relevant indicator. We used interrupted time-
series analysis based on the methodology from Cochrane Effective Practice and 
Organisation of Care (EPOC) resources when examining these data 140. This 
methodology is also recommended for AMS-studies as it is a strong design with high 
validity if time-varying confounding is considered 146. This was possible because 
control wards were included in the study. In December 2015, when the Norwegian 
Action Plan against antibiotic resistance was released, we chose to end data collection 
of the time-series data because the release of the action plan could potentially have 
made an impact on the time-series data, but also because it is unlikely that the 
interventions would have a prolonged effect beyond this date.  
 
Attrition bias 
Only 1 patient withdrew from the study, minimizing the risk of a biased study 





Power calculations were performed to assure that we included enough patients to see 
an effect of the interventions in study 1. Calculations were based on an expected 
increase in adherence to guidelines of 20% in each intervention ward, an assumption 
which did not hold in the intervention study. There was however very limited 
information informing the assumptions of the calculations, like the baseline degree of 
adherence in our hospital setting and the effect that could be expected in our setting. 
To overcome these barriers, a pilot study could have been performed, providing 
baseline data for calculations and secure sufficient power to analyse effect of 
interventions at each intervention ward.  
When performing sample size calculations, we did not incorporate an intra-cluster 
correlation coefficient (ICC) or comparison with a control group in the calculations, 
which is a study limitation. Data informing calculations of the ICC-coefficient was 
not available at this time, but an estimation could possibly have been included, based 
on previous literature. We did however calculate the ICC-coefficient when data was 
available, based on adherence to guideline, showing that the ICC-coefficient for this 
outcome was 0.012 with a 95% CI of (0.003, 0.053). 
 
5.1.2 External validity 
Study population 
External validity reflects how generalizable the findings are to other settings. Our 
studies were performed in medical wards at three hospitals in Western Norway, 
within specialties of pulmonary medicine, infectious diseases and gastroenterology. 
We included almost all patients with infectious diseases which received antibiotics 
during admission, which increases generalizability. Inclusion and exclusion criteria 
and patient characteristics are described for all studies, making assessment of study 
population transparent. Patients who did not receive antibiotics during admission 
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were not included in this study and it is therefore a possibility that we missed patients 
in whom antibiotics should have been initiated.  
Clinical context 
Norway has low levels of antibiotic resistance in bacterial isolates from clinical 
specimens, which could affect the way clinicians look at the level of urgency with 
regards to antimicrobial resistance. The findings from study 1 may be generalizable 
in settings with similar levels of resistance and similar egaliatarian hospital systems 
and culture. The experiences from study 1, with regards to designing and 
implementing interventions and involving clinicians in target setting can be useful for 
all those who have a healthcare system which are less hierarchical.  
Antibiotic guidelines in Norway recommend mostly narrow-spectrum antibiotics, 
belonging to the WHO AWaRe access group as first line treatment, which may be 
impossible in other settings with different resistance patterns. Results from study 2 
may therefore be more easily applicable in settings with similar resistance and 
prescribing guidelines, like the Nordic countries or the Netherlands. Guidelines 
should however always represent best practice and as similar studies from other 
countries also have found favourable patient outcome when guidelines are used, the 
study contributes to the total evidence base, highlighting guideline adherent 
prescribing as safe and effective.  
A thorough assessment of barriers and fascilitators that could affect the 
implementation of interventions in each of the study wards might have revealed 
cultural and contextual differences that could be addressed before and during the 
implementation of interventions and helped in interpretation of the variability of 
effects seen across the study wards 105, 135, 146.   
Study 3 describes the prescribing patterns from admission to discharge and analyses 
factors associated with non-adherence to guideline. The use of AWaRe categories to 
analyse individual patient data throughout the admission is new. This method could 
be useful in all other hospitals to understand local prescribing challenges and identify 
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targets for change. The factors associated with non-adherence to guidelines are likely 
to be generalizable to hospitals which have the same organisational model as 
Norwegian hospital. 
Temporal (time-dependent) factors 
Over the last 5 years, the awareness of AMR has increased in all areas where 
antibiotics are utilized, and since 2016, all public hospitals in Norway have been 
obliged to implement AMS programmes. As awareness is an important first step in 
behaviour change, this could possibly influence the generalizability of results, leaving 
the hospitals more prepared and ready for change related to optimizing antibiotic use 
now, than during the intervention study in 2014.  The guidelines for antibiotic use in 
hospitals have not changed notably since they were released in 2013 and neither has 
resistance rates in Norway 23, 24. The results from study 2, showing that guideline 
adherent prescribing is associated with improved clinical outcomes are still relevant 
and similar results are expected in other settings where guidelines are based on 
available evidence on disease aethiology, effective bug-drug combinations and local 
resistance patterns. It is however vital to secure that the guidelines are updated 
regularly to secure that clinicans can continue to trust in the recommendations given.   
 
In study 3, we looked at the prescribing process from different angles. As AWaRe 
categories, guidelines and clinical practice change, the results may become less 
relevant, but as we have reported all adjustments made to fit the Norwegian context, 
it is easy to compare with future changes and categories. The findings may also serve 
as a relevant and important baseline measurement for future comparisons when 
efforts have been made to improve prescribing. One important area which is currently 
highly debated, is the duration of treatment 147. It is likely that we will see a 
substantial change in the duration of treatment in the following years and studies 
documenting length of treatment in different settings are important to track the 




Data from electronic medical records were readily available, although the data 
extraction process was cumbersome. Electronic medical records are however 
primarily made for documenting treatment of patients, secondly for economically 
related information, and not for research. Data may be missing or not standardised, 
leaving room for interpretation. Through applying a standardized case report form, 
we tried to avoid interpretation, but a limitation to these studies is that six researchers 
took part in manual data collection and that individual researchers could have 
interpreted data differently. Manual plotting of data, limited to 3 people, could also 
have introduced errors in the database. All plotted data was validated in a separate 
process against the paper CRFs and if data was missing, completion of data was 
sought by revisiting the patient’s electronic medical record to record missing data. 
Additionaly, data on 30 day-mortality were extracted from hospital administrative 
systems and compared with manually collected data from hospital A, showing that 
only 0.47% of patients had the wrong outcome registered in our database. Assuming 
that the error rate was similar for other variables, the reliability of the data collected is 
good.  
5.2 DISCUSSION OF RESULTS AND LESSONS LEARNED 
5.2.1 Effect of  AMS-interventions 
Clinical antibiotic guidelines are part of the foundation for AMS-programmes and 
adherence to guidelines is an important goal 134.  Norway is still at an early stage in 
implementing AMS-programmes, and reliable antibiotic guidelines, constituting best 
practice, are important in this work. We have shown that adherence to these 
guidelines is associated with favourable clinical outcomes across a wide range of 
common infectious diseases in Norwegian hospital settings. Norwegian studies 
focusing on appropriate, guideline-adherent antibiotic prescribing in hospitals are 
scarce. In a  Norwegian paper from 2002, Berild et al found that compliance to local 
guidelines in a paediatric ward were more than 90% 148. In comparison, we found that 
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adherence to guidelines increased from 60% at baseline to 66% post interventions 
across all interventions wards. Davey et al found in their review a 15% increase in 
appropriate prescribing, from 43 to 58 %, following various interventions to improve 
antibiotic prescribing to hospital inpatients 105.   
 
Lower respiratory tract infections (LRTIs) are a frequent cause of hospital 
admissions. Although we saw in study 3 that other groups of infections were more 
likely to receive antibiotics non-adherent to guideline, the high volume of patients 
with LRTIs makes this group of diagnoses an important target for AMS-interventions 
because of the large potential impact on total antibiotic use in hospitals. LRTIs 
accounted for more than 80% of patients included in our pulmonary intervention 
wards, where we found a 14% increase in guideline-adherence post-interventions. 
Our findings are in line with Schouten et al, who found in their cRCT, targeting 
LRTIs, that guideline-adherent prescribing increased from 50.3% to 64.3% 149.  A 
single site study in Northern Norway, targeting community acquired pneumonia 
(CAP) and AECOPD through audit with feedback with local target setting in a ward 
of pulmonary medicine, found an increase in adherence from 61.7% to 83.8% 150.  
Baseline adherence was similar to our intervention wards and the increase in 
adherence was comparable to the effects aimed for in our study. Although we were 
far from reaching our aim of a 20% total increase in guideline adherence across 
intervention wards, the 13% and 14% increases that we saw at the pulmonary 
intervention wards were encouraging and are likely to reflect that the focus of the 
interventions fitted the profile of the pulmonary wards to a greater extent than the 
wards of infectious diseases and gastroenterology.  
 
Studies investigating AMS-interventions usually report process outomes or quality 
indicators, like obtaining blood cultures, adherence to guidelines, use of broad-
spectrum antibiotics, timeliness of antibiotics, i.v. to oral switch and review of 
antibiotics 105, 151. There has been a demand for studies including both intended and 
unintended consequences reporting both process outcomes, clinical patient outcome, 
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financial- and microbiological measures and adverse events, like C.diff-infections 33, 
146. Schweitzer et al found that most studies did not report clinical and 
microbiological outcome data and that studies in the community setting were of 
higher quality 133. In addition to adherence to guidelines and use of broad-spectrum 
antibiotics, we included mortality, readmission and length of stay in our intervention 
study, but found that the interventions did not affect patient outcome. In their 2017-
review, Hulscher et al reported that following guideline recommendations were 
associated with improved clinical outcomes, reduced costs, mortality and frequency 
of adverse events 134. In study 2, we also found that adherence to guidelines improved 
mortality and length of stay, but we did unfortunately not include financial measures 
or adverse events.  
 
We found a decreasing trend in- (-6.8 DDD/100 bed days, p=0.0.12) and drop in level 
of broad-spectrum antibiotic use pre- and post intervention (12 months: -29.3 
DDD/100 bed days, p= 0.027, 18 months: -42.9 DDD/100 bed days, p= 0.016) for the 
audit with feedback group, but the groups receiving academic detailing or the control 
group did not show the same results. Both audit with feedback and academic detailing 
are shown to be effective, although audit with feedback may be perceived as more 
stringent 105. The effect of audit with feedback on broad-spectrum antibiotic use was 
seen across both the specialty of pulmonary medicine and infectious diseases and the 
ward of infectious diseases contributed to this result to a great extent. The 
contribution to the effect from the two specialties could potentially be somewhat 
different, with pulmonary wards showing a more promt response to interventions, as 
seen when adherence to guidelines was measured. The ward of infectious diseases 
may have needed more time to digest the results from the audit and be convinced to 
adjust practice, as antibiotic prescribing is right in the heart of their specialty. A 
possible explanation is that the intervention increased awareness and organizational 
readiness for change and that this was not evident during the short post-intervention 
period with patient-level data, but could be seen in the long-term follow up of the use 
of broad-spectrum antibiotics 152. Stenehjem et al saw in their cluster randomized 
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intervention study, including 15 small hospitals without routine ID-consultation 
available or an AMS-programme present prior to study initiation, that only the 
hospitals with the most intense intervention program (program 3), had a reduction in 
broad-spectrum antibiotic use 153. Program 3 hospitals received advanced antibiotic 
stewardship education and tools, access to an infectious disease hotline, antibiotic 
utilization data, audit with feedback for the majority of antibiotics, locally controlled 
antibiotic restriction and an ID-trained clinician who approved restricted antibiotics 
and reviewed microbiology results. Broad spectrum antibiotic use had a rate ratio of 
0.76 with 95% CI (0.63, 0.91) in the program 3 hospitals in the intervention period 
compared to the baseline period 153. In comparison, none of the hospitals included in 
our study had AMS-programmes, all intervention wards were provided antibiotic 
utilization data, and all had access to ID-physicians for guidance.  
 
Sustainability of effects following AMS-interventions is challenging and should be 
assessed, as evidence suggests that removal of interventions are associated with a 
reversal of effects 105. To have a sustained effect of the interventions performed 
within the interventions study, repeated audits with feedback as part of normal 
clinical practice would then have to be implemented. Within the electronic medical 
record that was in use at the time, automatic data extraction on the use of antibiotics 
was not possible. The most challenging part of this study was data collection. 
Automated data extraction would make repeated audits feasible to implement and 
collection of data on antibiotic use easier. During the time that has passed since this 
study was performed, a new computerized physician order entry (CPOE)-system has 
been put in place, and progress have been made with regards to data extraction. To 
assess sustainability of interventions, we used antibiotic sales data from the hospital 
pharmacies, a commonly used source of outcome data, which has both its limitations 
and advantages 146.  Data are readily available and gives valuable information about 
the amount of broad-spectrum antibiotic use, but the lack of connection between 
indication for treatment and antibiotic use makes data interpretation challenging. 
When antibiotic sales data are used as an outcome measure, care should be taken to 
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avoid that shifts in prescribing practice goes undetected, possibly leading to 
unintended consequences, such as increased rate of adverse events (e.g. C.Diff-
infections) or poorer patient outcome 146.  
5.2.2 Local target setting  
The intervention sessions were short – normally one hour – and was to include both a 
presentation from the intervention team and a discussion between clinicians and the 
team, aiming to also find one or two local targets in addition to the general target of 
increased adherence to guidelines.  The process of finding local targets was not 
defined good enough from the research team during planning, leaving only one ward 
and intervention team with a consensus on a local target which was also possible to 
measure through the planned data collection. Two wards could not achieve consensus 
on 1-2 targets, one ward did not identify any targets and the fourth ward wanted to 
focus on reducing prescription of ciprofloxacin for inflammatory bowl disease (IBD) 
in exchange for co-trimoxazole. Treatment of IBD was not included in the antibiotic 
guidelines, had limited evidence and a limited number of patients admitted during 
study period. This was an important subject for the clincians, but it was not possible 
to see an effect on the outcome measure of adherence to guidelines in general or the 
local target. For the intervention ward that managed to identify a local, measurable 
target, the effect was very good, with a 30% increase in targeted prescribing 
behaviour, suggesting that this is indeed a very useful intervention when properly 
implemented. It may have been more difficult for the intervention wards receving 
academic detailing to set a target, with only individual patient cases and clinical 
experience as the foundation. Audit results were more tangible and clincians could 
see for themselves objective descriptions of the wards’ prescribing at an aggregated 
level. Introducing SMART goals (specific, measurable, attractive/acceptable, realistic 
and time-bound) or the three questions asked within the Model for Improvement1 
                                              
1 1. What are we trying to accomplish?  2. How will we know that a change is an improvement? 3. What changes can we 
make that will result in improvement? 
65 
 
could have helped clinicians and intervention teams in the process of finding local 
targets and ensured that all targets proposed were measurable 128, 154, 155.  
 
5.2.3 Clinical context and AMS 
The remarkable difference in the impact of interventions between the specialties was 
an interesting finding. Both audit with feedback and academic detailing are 
considered effective approaches for improving prescribing practices 105. Adherence to 
guidelines increased at pulmonary intervention wards, regardless of the intervention 
applied, but the same effect could not be seen in other specialties. The fact that we 
did not find similar effects for the specialties of infectious diseases and 
gastroenterology, contributes to the evidence saying that effect of AMS-interventions 
is dependent both on the context in which interventions are implemented and how 
they are implemented 105, 146. As previous studies have primarily looked at the 
difference in prescribing practices between medical and surgical specialties, our study 
suggests that medical specialties can not be treated equally when interventions are 
applied 118, 156. The context and culture of each ward or department, baseline 
performance and the people involved in performing the interventions are likely to 
influence the results and should be taken into account 157. To succeed with behaviour 
change, we therefore need to understand the context and culture in which we are 
implementing our interventions. When designing and implementing the interventions, 
we included clinicians well known in the intervention wards. Interventions were 
performed by teams of physicians and pharmacists and in all but one ward 
(gastroenterology), local champions were involved. They tailored feedback 
presentations to fit the need of the intervention wards and one added information 
about a previous local outbreak with resistant bacteria (VRE) to strengthen the 
message conveyed about the necessity of prudent prescribing. The outcome of an 
intervention study will be strongly affected by the barriers and fascilitators for 
implementation of the proposed interventions, including readiness for change in the 
organisation. The study was performed prior to the release of the Norwegian Action 
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Plan Against Antibiotic Resistance - when the focus on AMR in the hospitals were 
more limited - and a formal assessment of readiness for change was not made. 
Warrenman et al investigated determinants of antimicrobial prescribing in studies 
published from 2007 to 2017 and noted the increase in awareness of AMR during this 
period 158. Clinicians must constantly weigh the threat of AMR against the fear for 
underprescribing for a sick patient.  The awareness of AMR, combined with a sense 
of urgency related to AMR both in the local and global context and belief in 
guidelines as best practice are likely prerequisites for successful implementation of 
clinical guidelines on antibiotic prescribing. A more in-depth understanding of the 
challenges of each ward, why they prescribe the way the do and an assessment of 
barriers and fascilitators for implementing interventions in the separate wards could 
have improved the intervention outcome or at least helped explain the variability in 
impact that was seen across specialties and wards. The use of a framework for 
behavioural change during planning and reporting of the intervention study could also 
have helped with tailoring interventions and learning from the study findings 135, 136. 
 
5.2.4 Empirical antibiotic prescribing 
In study 3 we found that non-adherence was more likely at hospitals A and C, 
compared to hospital B and also when antibiotics were prescribed at the ward, 
compared to the emergency room. As almost 80% of antibiotics were initiated in the 
emergency room (ER), the finding suggests that physicians working primarily in the 
emergency wards are vital in securing guideline-adherent prescribing when initiating 
treatment. The ER-environment is hectic, and clinicians have identified the pace of 
the emergency departments as a structural barrier to AMS-programmes 129. When the 
intervention study was performed, prescribing in the emergency rooms were mainly 
performed by junior physicians, a category of doctors which have reported to rely 
more on prescribing guidelines that their seniors 76. The choice of treatment made in 
the ER is vital in the treatment of serious infections and also influence the choice of 
therapy at the wards for a long time, as seen in our third study, where mean day of 
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modification of empirical treatment was 3.6 days 159. In study 2 we found that 
empirical antibiotic prescribing adherent to guidelines is associated with favourable 
patient outcome, both in terms of mortality and length of stay.  This prescribing was 
mainly performed in the ER. We did however not see any association with guideline 
adherence and readmission. Schuts et al also showed in their 2016 systematic review 
the benefits of adherent prescribing, with a relative risk reduction for mortality of 
35% when guidelines were followed. Including ER-physicians in AMS-interventions 
would likely have increased the impact of interventions on adherence to guidelines 
and should be considered for future AMS activities. The national antibiotic 
prescribing guideline is a cornerstone in the work performed both nationally and 
locally to implement AMS in all hospitals. With this study, we have added a piece of 
evidence suggesting that guideline adherence is safe and should be regarded best 
practice in Norwegian hospitals. Securing access to updated, clinical prescribing 
guidelines should therefore be of prime importance in the work against antimicrobial 
resistance as they benefit both the patient and the environment. 
 
5.2.5 Are we AWaRe? 
In study 3 we applied the AWaRe categories found in the 2017 WHO Essential 
Medicines List (EML) to describe and analyse the pattern of antibiotics prescribed 
throughout the hospital stay 102. Not all antibiotics used in the Norwegian setting were 
included in AWaRe and we therefore made a modified list were mecillinam, 
pivmecillinam, methenamine and tobramycin were included in the Access category, 
and cefuroxime was added to the Watch category. The updated version of the WHO 
EML from June 2019 would not impact the results in our study 101. The use of 
metenamine was very limited in our hospital population. Both in our study and in the 
studies by Hsia et al and Budd et al, the Access group was comprised of the core 
Access antibiotics only 160, 161.  In the English adaptation of the AWaRe-list, the 
England AWaRe index, they chose to add methenamin to a “other” category and 
tobramycine was added to the Watch-category 160. If our categorisation was to be 
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used in the Norwegian primary care setting, the use of an “other”-category would be 
appropriate also for us. The use of methenamine is extensive in this setting and 
methenamine is excluded from the measurement of total antibiotic consumption in 
primary care when the progress towards the goals in the Norwegian Action Plan 
against AMR is assessed 12, 23.  Norwegian antibiotic guidelines are prudent and 
recommends access antibiotics for most infections as first line empirical regimen. We 
found that when guidelines were followed, 89% of antibiotic regimens were 
comprised of antibiotics within the access group only. We have not been able to 
identify other studies looking at patient level prescribing and adherence to guidelines 
in relation to AWaRe-categories, but Hsia et al found that based on antibiotic sales 
data, approximately 85% of oral antibiotics prescribed for children in Norway were 
Access antibiotics 161. In the adjusted, England-adapted AWaRe-index, the status of 
37 antibiotics were determined or changed compared to the original WHO AWaRe 
categories, including moving clindamycin and 1st generation cephalosporins from 
Access to Watch due to the association with increased risk of C. Difficile infections 
and moving carbapenems from Watch to Reserve 160. In the study by Hsia et al, 
approximately 75% of oral antibiotics prescribed for children in the UK were within 
the Access category. In comparison, with the adjusted index, 49.7% of prescribed 
antibiotics were in the Access-category in the acute hospital sector in England 160. 
The variations in classifications of antibiotics in the limited number of studies which 
have made use of the AWaRe categories, makes it challenging to compare results 
between studies. Local resistance patterns may warrant adjustments in AWaRe 
categories in different countries but including a more comprehensive list of 
antibiotics by the WHO could also help future studies wanting to utilize AWaRe as a 
tool for AMS-initiatives.  
5.2.6 Duration of therapy 
Duration of antibiotic therapy has been heavily debated the last few years, sparked by 
the BMJ-paper called “The antibiotic course has had its day” by Llewelyn et al in 
2017 147. There has been limited evidence for the duration of therapy which have been 
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recommended in current clinical practice guidelines and there is an increasing 
evidence base proposing that “shorter is better” 162-166. We found in study 3 that the 
duration of treatment was surprisingly similar across a wide range of diagnoses. 
There seems to be a need for adjustment of both guidelines and clinical practice to 
incorporate new evidence, but also for more quality research providing a good 





Through this research project we have added to the knowledge needed to implement 
antibiotic stewardship in Norwegian hospitals: 
The impact of implementing different AMS-interventions on adherence to national 
antibiotic guidelines differed between specialties, while the use of broad-spectrum 
antibiotics declined (level and trend) across intervention wards receiving audit with 
feedback, regardless of specialty.  Although local target setting was challenging, an 
impressive change in prescribing behaviour was observed when clinicians were able 
to set local targets, with the backdrop of audit data. Consequently, audit with 
feedback is an essential AMS-intervention that hospitals should perform, and 
engaging clinicans in local target setting should be encouraged. The impact of 
interventions will differ between departments, wards and/or patient population, 
depending on culture, context and tailoring of interventions.  
Patients who received empirical treatment adherent to the national antibiotic 
guidelines had a significantly lower in-hospital and 30-day mortality compared to 
patients who received non-adherent treatment, and there was a trend towards shorter 
length of stay. This adds to the evidence suggesting that prescribing according to 
guidelines provides the best treatment for patients and should be aimed for. Since the 
majority of patients were prescribed empirical antibiotic treatment in the emergency 
room, antibiotic stewardship efforts should include the first line clinical staff that 
inhabits the emergency rooms. The vast majority of patients continued antibiotic 
therapy after discharge, contributing significantly to the total days of antibiotic 
therapy, and duration of antibiotic therapy was similar across very different groups of 
diagnoses. This suggests that therapy can be shortened safely for many patients, but it 





Place of initiation of empirical therapy (hospital and ward vs ER), admittance from an 
institution and group of diagnosis were associated with non-adherence to clinical 
practice guidelines in our study. A deeper understanding of the reasons for non-
adherence and an assessment of cultural and contextual factors affecting prescribing 
will be important when developing future interventions and implementation strategies 
in hospital settings. Analysis of patient-level, antibiotic prescribing data from 
admission to discharge gave valuable insight in the local prescribing processes and 
identified new targets for AMS-interventions. Similar analyses should be performed 
to inform stewardship work both inside and outside of study contexts. 
 
WHO AWaRe-categories provided a useful system for grouping and analysing 
antibiotic regimens throughout the hospital stay, although modifications had to be 
made to include all antibiotics prescribed in this study setting. If more studies used 
this framework, it would be easier to compare antibiotic prescribing between 
countries and also see how guidelines and AWaRe-categories are connected in 
different parts of the world.  
 
Even though the studies were performed in three Norwegian hospitals, we believe 
that methods and findings will be applicable in other clinical settings where antibiotic 
prescribing and related patient outcomes is to be analysed and improved.  
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7. FUTURE PERSPECTIVES 
1.  In all three studies included in this thesis, we excluded patients with a diagnosis 
for which there was no recommendations to guide empirical therapy, such as 
“infection – unknown focus.” The treatment of- and patient outcomes related to the 
group of patients with very uncertain diagnoses on admission should be further 
investigated.  
 
2. Future studies should include both severity of infections and an evaluation of non-
adherence as under- or overtreatment, to further understand why non-adherence is 
associated with increased mortality. Adding information about severity of infections 
in a structured and easily detectable way in electronic medical records and medication 
charts is warranted.  
 
3. To achieve increased and sustained impact of antibiotic stewardship interventions, 
they should be based on a thorough understanding of current practice, barriers and 
fascilitators to interventions and the context and culture in which they are 
implemented. Future studies should incorporate qualitative studies to analyse these 
dimensions before large scale interventions studies are initiated. This includes finding 
out how to best enable the clinicians – in every way-, so that correct prescribing is 
made easy.   
 
4. Electronic medical records (EMR), including computerized physician order entry 
(CPOE) and clinical decision support systems (CDSS) should be incorporated in both 
hospital and primary care to ease the prescribing process and to allow automated data 
extraction. EMR and CPOE systems should be designed in a way that allows 
indication for treatment and corresponding medicines to be easily identified. 
Automated audit and feedback systems can then be implemented to inform practice 
on all levels, from the individual physician receiving feedback on his or her own 
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prescribing behaviour, to aggregated data on ward, department, hospital, regional, 
national and even global levels.    
 
5. More studies investigating patient-level antibiotic prescription data and factors 
associated with non-adherence to guidelines would be valuable to compare our 
findings with hospitals across the world. The use of WHO AWaRe to group antibiotic 
regimens on a patient level has – to the best of our knowledge – not been performed 
previously and should be repeated in other settings. An extended list of AWaRe 
categories, including all available antibiotics, should be put in place as a reference for 
future studies to avoid that all countries or regions make their own version, which 
makes comparison difficult. Future studies should also present data for individual 
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The effect of antibiotic stewardship
interventions with stakeholder involvement
in hospital settings: a multicentre, cluster
randomized controlled intervention study
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Abstract
Background: There is limited evidence from multicenter, randomized controlled studies to inform planning and
implementation of antibiotic stewardship interventions in hospitals.
Methods: A cluster randomized, controlled, intervention study was performed in selected specialities (infectious
diseases, pulmonary medicine and gastroenterology) at three emergency care hospitals in Western Norway.
Interventions applied were audit with feedback and academic detailing. Implementation strategies included
co-design of interventions with stakeholders in local intervention teams and prescribers setting local targets
for change in antibiotic prescribing behaviour. Primary outcome measures were adherence to national guidelines,
use of broad-spectrum antibiotics and change in locally defined targets of change in prescribing behaviour. Secondary
outcome measures were length of stay, 30-day readmission, in-hospital- and 30-day mortality.
Results: One thousand eight hundred two patients receiving antibiotic treatment were included. Adherence to guidelines
had an absolute increase from 60 to 66% for all intervention wards (p = 0.04). Effects differed across specialties and
pulmonary intervention wards achieved a 14% absolute increase in adherence (p = 0.003), while no change
was observed for other specialties. A pulmonary ward targeting increased use of penicillin G 2 mill IU × 4 for
pneumonia and COPD exacerbations had an intended increase of 30% for this prescribing behaviour (p < 0.001).
Conclusions: Pulmonary wards had a higher increase in adherence, independent of applied intervention. The effect of
antibiotic stewardship interventions is dependent on how and in which context they are implemented. Additional
effects of interventions are seen when stakeholders discuss ward prescribing behaviour and agree on specific
targets for changes in prescribing practice.
Keywords: Antibiotic stewardship, Intervention, cRCT, Audit with feedback, Academic detailing, Hospital, Goal setting
Background
Globally, the overuse and misuse of antibiotics, espe-
cially broad-spectrum agents, has accelerated the devel-
opment and selection of resistant bacteria [1–3]. The
increase in broad-spectrum antibiotic prescribing cannot
be explained by increased antibiotic resistance alone [4].
Antibiotic stewardship programs have been introduced
to hospitals worldwide to promote more prudent anti-
biotic use [5, 6]. The basis of stewardship programs are
evidence based clinical guidelines for antibiotic prescrib-
ing to ensure effective treatment for individual patients,
while minimizing development of antimicrobial resistance
(AMR). Adherence to antibiotic guidelines varies among
countries and institutions [6]. Interventions like audit with
feedback, providing a summary of clinical performance
over time and educational outreach through academic
detailing have been shown to be effective in increasing
* Correspondence: jannicke.slettli.wathne@sav.no; ismith@who.int
1Department of Clinical Science, University of Bergen, Bergen, Norway
8Innovation, Access and Use, Department of Essential Medicines and Health
Products, World Health Organization (WHO), Avenue Appia 20, 1211 Geneva
27, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wathne et al. Antimicrobial Resistance and Infection Control  (2018) 7:109 
https://doi.org/10.1186/s13756-018-0400-7
adherence. However, the need for studies addressing
cultural, contextual and behavioural determinants when
developing, implementing and reporting stewardship in-
terventions has been highlighted [6–9]. There is also a
need for more studies that apply behaviour change theory
to investigate effect on antibiotic use across hospitals, spe-
cialties and diagnoses to help identify the most effective
means of implementing interventions that are transferable
and generalizable [6, 10, 11]. We report here the findings
of a multicentre, cluster randomized controlled interven-
tion study, investigating the effect of behaviour change in-
terventions with stakeholder involvement and local target
setting for change in antibiotic prescribing [12].
Methods
Definitions
Substances of ATC-group J01 (Antibacterials for sys-
temic use), metronidazole tablets (P01AB01) and vanco-
mycin tablets (A07AA09) were included in the definition
of antibiotics for this study [13]. Broad-spectrum antibi-
otics were defined as penicillins with enzyme inhibitor
(J01CR), 2. and 3. generation cephalosporins (J01D C-D),
carbapenems (J01DH) and quinolones (J01MA), the five
groups targeted in the National Action Plan Against
Antibiotic Resistance in Health Services [14, 15].
Study design
This prospective, cluster randomized, controlled inter-
vention study was performed within three specialties at
three emergency care and teaching hospitals as a parallel
group study with three arms (Table 1).
Participants and data collection
Eligible clusters were wards within one of the medical
specialties; infectious diseases, pulmonary medicine and
gastroenterology at hospital A, B and C in Western
Norway. Specialties were selected based on infectious
diseases and pulmonary medicine having the highest
consumption of antibiotics in the included hospitals.
Gastroenterology was included since hospital B had a
joint medication storage area for the ward of pulmonary
medicine and the ward of gastroenterology. Hospital A
and B were tertiary care hospitals with 1100 and 600 beds,
respectively. Hospital C was a secondary care hospital
with 160 beds. For description of case mix, see Table 2.
Patients who received antibiotics during hospitalization
and were discharged from the study wards in the time
period from 10th of February to 11th of July 2014 were eli-
gible for inclusion in the study. Patients who received anti-
bioticprophylaxis, had orthopaedic prosthesis infections, or
had a hospital stay < 24 h or > 21 days were excluded.
Patients whose indication for treatment was not in the anti-
biotic guideline or whose antibiotics were discontinued at
day 1, was excluded. Only the first stay of readmitted
patients was included. Patients were included consecutively.
Patient data were collected manually from electronic med-
ical records. Data collected included patient demographics,
indication for antibiotic treatment, antibiotic prescribing,
microbiological test results, estimated glomerular filtration
rate (eGFR) on admission, length of stay, 30-day readmis-
sion, in-hospital and 30-day mortality and admittance
from- or discharge to other hospitals or nursing homes. In-
dications for antibiotic treatment were registered as docu-
mented in the medical record and not assessed for validity.
Broad-spectrum antibiotic use for study wards in the
period 2013–2015 was collected from the hospital pharma-
cies sales statistics and adjusted per 100 patient bed days.
Interventions
The primary intervention aim was to increase adherence
to The National Guidelines for Antibiotic Use in Hospitals
(hereafter guidelines), across diagnoses [16]. Each hospital
assigned local intervention teams of 1–2 physicians and 1
pharmacist to co-design and implement the interventions.
Authors I.S and J.S.W developed initial intervention con-
cepts, which were discussed in a regional meeting with all
project participants. Each intervention team then refined
the interventions to fit their local context. A common
presentation template was prepared for all intervention
sessions with information about antibiotic resistance, the
national antibiotic guideline, local antibiotic sales statistics
and principals of antibiotic dosing. All intervention teams
modified this material to fit the individual wards. Aca-
demic detailing sessions focused on recently admitted in-
fectious diseases patients, including cases with treatment
both adherent and non-adherent to guidelines. The teams’
selection of patient cases decided the focus in wards re-
ceiving academic detailing.
Audit with feedback wards had predefined target areas of
pneumonia and COPD exacerbations, as these patients
were frequently admitted to both intervention wards. Fifty
patients with these diagnosis were included consecutively
from February to April 2014 to get a reasonable overview
of prescribing practice over the given time period, without
excessive workload for the intervention teams. For the audit
data, intervention teams assessed adherence. The level of
detail and focus in the feedback was at the discretion of the
teams and varied between the two feedback wards.
Intervention ward physicians were invited to academic
detailing- or audit with feedback- group sessions in May
2014, led by local intervention teams. No specific threshold
for acceptable attendance was defined, but more than one
meeting was held if the intervention team considered the
attendance at the first meeting to be too low. Physicians
present at the main session at each ward were invited to
identify one or two specific challenges to be addressed as
local targets for improvement of antibiotic prescribing
based on discussions during the session. Specific actions to
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achieve targets were not included in the target discussions.
For details of interventions, see Table 1.
Outcomes
Primary outcome measures
1) Adherence to guidelines was assessed on the second
day of treatment to allow sufficient time for patients
to be reviewed by study ward physicians and
measured as percentage of correctly prescribed
empiric treatment (choice of active substance)
before and after interventions [16]. CRB-65 was
not routinely documented, so pneumonia and
severe pneumonia was assessed together (both
empiric treatments assessed as adherent). All
hospitals were committed to use the national
guideline, as recommendations were appropriate
with regards to local antibiotic resistance patterns.
2) Use of broad-spectrum antibiotics was assessed as
DDD/100 bed days in time series before and after
intervention. Broad-spectrum antibiotic use was
selected as an outcome measure because the guidelines
mainly recommend narrow-spectrum antibiotics as
empiric treatment and a shift towards guideline
adherent prescribing was expected to cause a
reduction in broad-spectrum antibiotic use.
3) Change in locally targeted prescribing behaviour
was assessed according to the defined targets and
compared before and after interventions.
Secondary outcome measures were length of stay,
30-day readmission and mortality (all cause in-house
and 30-day mortality). Patient outcomes were measured
to ensure that the interventions did not have any nega-
tive consequences for patient treatment.
Sample size
As baseline adherence to guidelines was unknown in
Norway, calculation of the sample size prior to the study
was challenging. According to the original research
protocol, we assumed an absolute 20% improvement in
adherence from 50% pre-intervention to 70% post-inter-
vention for each cluster. Given a power of 80% and a
type 1 error of 5%, the smallest number of subjects
needed to detect this difference was 93 both before and
after the intervention. Although this was sufficient for
the current study, we calculated at least 155 patients be-
fore and after intervention to answer additional research
questions listed in the original protocol. However, the
sample size calculations did not include intra-cluster
correlation coefficient (ICC) or comparison with a con-
trol group. Based on pre-intervention data of adherence
to guideline, ICC coefficient for this outcome was 0.012
with 95% CI (0.003, 0.053).
Randomization
Authors I.S and J.S.W. performed randomization and
assigned clusters to interventions by drawing lots of hos-
pital and intervention groups per specialty. Across the
hospitals, infectious diseases and pulmonary medicine re-
ceived both academic detailing and audit with feedback
and had a control group. Only two of the hospitals had
specific gastroenterology wards, so this specialty received
only one intervention and had a control group (Table 1).
Blinding
Prescribing physicians at the wards were not informed
about the study being performed during the baseline
period and were at that point blinded to intervention
group, with the exception of the physicians assigned to
the project teams. Control ward physicians were blinded
throughout the study period.
Assessment of adherence to guidelines was performed
blinded to the intervention- or treatment group, by using
syntax in SPSS. An adherence variable was generated,
combining the variable indication for treatment with the
variable for prescribed treatment. First choice of empiric
therapy was coded as adherent. Manual adjustment of ad-
herence of antibiotic prescriptions was made in patients
with antibiotic allergies or kidney failure.
Statistical analysis
Analyses were performed both per intervention group and
per specialty, but due to fewer patients than expected in the
post-intervention period, analysis per cluster was not per-
formed. Differences in study group characteristics pre- and
post-interventions were tested using Pearson’s chi-square
test for categorical data and independent two-sample t-test
for continuous data. Pearsons chi-square test was also
applied to test adherence to guidelines pre- and
post-interventions for individual intervention groups and
specialties. To test whether percentage of adherence to
guidelines or patient outcomes in intervention and specialty
groups changed differently over time compared with the
control group, we evaluated the group-by-period inter-
action term in simple logistic or linear regression models,
as appropriate. Adherence to guideline or patient outcome
were dependent variables, with group of intervention (audit
vs control/academic detailing vs control) or specialty (e.g.
pulmonary medicine vs control/infectious diseases vs con-
trol) and period (before-after) were independent variables
together with the interaction term. The level – and trend
effect of broad-spectrum antibiotic use (sales statistics) pre-
and post-intervention was estimated with the Interrupted
Times Series (ITS) analysis method described by the
Cochrane Effective Practice and Organisation of Care
(EPOC) group [17]. All tests were two-sided and p-values
< 0.05 was considered statistical significant for all analyses.
Wathne et al. Antimicrobial Resistance and Infection Control  (2018) 7:109 Page 5 of 12
Statistical analysis was conducted using SPSS for Windows,
version 24 and Stata SE for Windows, version 15.
Results
Patients
Two thousand four hundred five admissions were eligible
for inclusion. After applying exclusion criteria, 1802 unique
patients were included in analysis, 1279 and 523 patients in
the pre- and post-intervention periods respectively
(Table 2). The study period was fixed due to time-limited
allocation of project resources and mandatory information
of included patients. Interventions were conducted later
than originally planned due to practical considerations at
the study wards. This caused skewness in data with two
thirds of the patients included pre-interventions (Table 2).
Patient characteristics were similar pre- and post-interven-
tions, except for some differences in distribution of diagno-
ses in the audit with feedback group (Table 2).
Primary outcomes
Adherence to guidelines
Across all intervention wards, adherence to guideline in-
creased from 60% to 66% (p= 0.04), but when compared
with the control group, this was not significant (Table 3).
The effect of interventions differed largely between the
specialties. Infectious diseases and gastroenterology wards
displayed no effect of interventions on adherence, while
pulmonary medicine wards displayed significant effect of
interventions compared to the control group (Table 3).
Academic detailing and audit with feedback increased total
adherence to guideline by 14% and 13% respectively (abso-
lute increase), in the pulmonary wards (not shown in tables).
The audit with feedback intervention specifically tar-
geted pneumonia and COPD exacerbations. For these
diagnoses, the pulmonary medicine ward increased
adherence by 12% and infectious diseases ward by 2%
(not shown in tables).
Use of broad-spectrum antibiotics
Interrupted time series analysis showed that the overall trend
of activity-adjusted broad-spectrum antibiotic use pre- and
post-interventions was significantly improved, as was the
level at 12 and 18 months post intervention for the audit
with feedback group (Appendix: Table 5 and Fig. 1). The
gastroenterology intervention ward had a significant decrease
in the use of broad-spectrum antibiotics at 3 and 6 months,
but it increased thereafter (Appendix: Table 5 and Fig. 1). No
significant change in broad-spectrum antibiotic use was seen
at the intervention wards receiving academic detailing, the
control group and for other intervention wards per specialty
(Appendix: Table 5 and Fig. 1).
Local targets
Intervention wards were invited to set local targets for fol-
low up after the intervention sessions (Table 4). The pul-
monary ward at Hospital A had a significant and intended
30% increase in the targeted use of Penicillin G 2 mill IU ×
4 for patients with pneumonia and COPD exacerbations
post intervention (p < 0.001). The use of Ciprofloxacin at
the ward of gastroenterology was reduced at all time points
following the intervention, though not statistically signifi-
cant (Appendix: Table 6). The other study wards either a)
did not reach consensus on targets b) did not identify any
targets or c) the identified target was not evaluable.
Secondary outcome measures
When analysed per intervention, there was a decrease of
0.7 days in the mean length of stay for patients in the
audit with feedback group (p = 0.037) (Table 2). In the
academic detailing group, 30-days readmission had an
absolute decrease of 7.4% (p = 0.044). Compared with
Table 3 Percentage of adherence to antibiotic guidelines in periods before and after interventions were implemented








InteractionbBefore n (%) After n (%)
Intervention
Control All specialties 350/169 174 (50) 84 (50) 0 0.998
Interventions All specialties 929/354 556 (60) 234 (66) 6 0.04 0.252
Academic detailing All specialties 451/172 265 (59) 111 (65) 6 0.188 0.353
Audit with feedback Infectious diseases +
Pulmonary medicine
478/182 291 (61) 123 (68) 7 0.111 0.265
Specialty
Pulmonary medicine Both interventions 427/162 249 (58) 116 (72) 14 0.003 0.034
Infectious diseases Both interventions 424/153 268 (63) 99 (65) 2 0.741 0.857
Gastroenterology Academic detailing 78/39 39 (50) 19 (49) -1 0.896 0.556
aBy chi-square test per group
bBy logistic regression of given group vs control wards (all specialties), giving the p-value for the interaction between group and period
P-values < 0.05 are given in boldface
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the control group, these findings were not statistically
significant. In-hospital death, 30-day mortality, 30-day
readmission and length of stay for the other groups were
not significantly changed (Table 2).
Discussion
This study highlights the effect of engaging local stake-
holders (physicians) in setting specific targets for change in
antibiotic prescribing behaviours. A specific target area,
which is easy to remember and act upon, makes it possible
to achieve change within a short timeframe, as observed in
the pulmonary ward at Hospital A where adherence to tar-
geted behaviour increased by 30%. Another finding was how
the effect of interventions differed across specialties. Both
interventions were more effective at the pulmonary wards,
than wards of infectious diseases and gastroenterology.
Interventions to improve antibiotic prescribing practices
have shown a 15% average increase in adherent prescrib-
ing in intervention wards, however the effect depends on
how they are designed and implemented [6, 18]. When
Schouten et al. tailored interventions to each intervention
hospital; they achieved an average 14% increase in adher-
ence to guidelines for empiric treatment of lower respira-
tory tract infections (LRTI). The level of change was very
similar for all the intervention hospitals, although it was
not stated how the patients were distributed across the
wards of internal- and pulmonary medicine [19]. Their re-
sults are comparable to our findings at the pulmonary
wards, with a 14% absolute change in adherence to guide-
lines, while it differs substantially from effects seen across
infectious diseases and gastroenterology wards. A single
site Norwegian study focusing on pneumonia and COPD
exacerbations within pulmonary medicine, added a pocket
guideline to their audit with feedback intervention [20].
From a baseline adherence of 62%, similar to our study,
adherence was increased by 22%.
Involving clinicians in identifying challenges, finding
solutions and setting local targets is both reasonable and
recommended and has previously proven effective in in-
creasing compliance to target behaviour [6, 21–23].
Jobson et al. increased the timeliness of antibiotics for fe-
brile patients with central lines presenting in the ED from
63 to 99% [23]. They exceeded their goal of 90% timeliness
through active engagement of the caregiving staff and the
use of multiple plan-study-do-act-cycles (PDSA-cycles)
[24]. At the pulmonary ward at hospital A, the audit data
made it easy for clinicians to identify local challenges and
set a specific, measureable, attractive and realistic target
for change in prescribing behaviour and we found a simi-
lar change of 30% increase in target behaviour.
The wards receiving audit with feedback had different
case-mix. In infectious diseases, 41% of patients were treated
for pneumonia and COPD exacerbations, compared to 71%
in the pulmonary ward. This could partly explain the lack of
effect seen in the infectious disease ward, as pneumonia and
COPD exacerbations were the selected focus for the feed-
back sessions. Empirical therapy according to guidelines
across diagnoses was the main outcome measure for all
intervention wards. Pre-audits at every intervention ward
would have made it easier to identify each ward’s prescribing
challenges, and tailor the interventions to context specific
improvement areas for each ward. As this study is
Table 4 Local targets set by study intervention wards and outcome for targeted change in prescribing practice





Increase the use of Penicillin G 2 mill IU × 4 to treat
pneumonia (CAP) and infectious COPD exacerbations





Reduce ciprofloxacin use for inflammatory bowel
disease, and shift to Co-trimoxazol
(indication outside national antibiotic guideline)
Too few patients with targeted indication to
assess outcome by indication.
Assessed by use of sales statistics. Reduction
in use of Ciprofloxacin at 3, 6, 12 and 18 months







- Reevaluation of initiated treatment on arrival to ward
and - after 48–72 h
- Increase use of CRB-65 and antibiotic guideline






- Increase use of Penicillin G 2 mill × 4 to treat infectious
COPD exacerbations
- Reassess length of iv-antibiotics for patients with
osteomyelitis
- Increase consultants presence in the emergency room
to increase guidelines adherence on admission
- Reevaluation of treatment during the patient stay





No target area identified. No target area identified
aBy chi-square test bBy Interrupted time series analysis (Appendix Table 6)
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intervening in the very heart of ID-specialists’ area of expert-
ise, it may also be a bigger challenge to advocate a shift in
prescribing practice towards general antibiotic guidelines,
limiting the autonomy of the prescriber [25].
The national guideline was published approximately
6 months prior to study initiation and some wards had
already started promoting its use [16]. A previous study
by Skodvin et al. showed that interns and residents heav-
ily relied on guidelines when initiating antibiotic treat-
ment [26]. This could have caused a positive shift in
prescribing practice already, decreasing the potential for
absolute effect of interventions. Including physicians
mainly working in the emergency room in interventions
could have given increased effects, but intervention and
control wards at the same hospital would then be chal-
lenging because of spill over effects between the wards.
Champions can play a powerful role in behaviour
change [25, 26]. Special emphasis was made on using local
champions for developing and implementing interven-
tions as they are familiar to the ward physicians, know
possible barriers and facilitators and could tailor the pre-
sentations to the ward’s needs. Local involvement could
also increase the chance of continuous work within the
area after study completion. An example of tailoring is
adding information about a previous local outbreak of
Vancomycin-resistant enterococci (VRE) to the audit with
feedback session at the pulmonary ward at Hospital A, to
increase local ownership. At the gastroenterology ward,
academic detailing was performed by an ID-physician.
During evaluation, he suggested that including a physician
from the gastroenterology ward could have increased the
ownership of the intervention and the identified target. In-
terventions were only applied at one time-point during
the study period. Adding more intervention sessions could
probably have increased the effects seen [6].
We aimed to achieve responsible antibiotic prescribing
practice in a complex hospital setting. This study is a “real-
life” study, including the most common infections treated
at hospitals in the western world and three specialties in
three separate hospitals where patterns of prescribing may
differ, as will patient mix. All three hospitals and specialties
contributed both to the intervention and control groups,
reducing the potential for confounding and increasing ex-
ternal validity of the findings. The study was initiated in a
“normal” clinical situation and not as a response to an out-
break. Random time effects should therefore be reduced.
Seasonality is likely, but the inclusion of control groups
within the same time period allow us to control for the ef-
fects. Findings should be generalizable to other hospital
wards within the same specialties and in settings with a
similar, relatively flat organizational structure.
The short post-intervention period and skewness of data
between pre- and post-intervention periods is the major limi-
tation to this study, caused by the fixed date for study period
when applying for study approval and the substantial work-
load for manual data collection of individual prescription
data. This also led to insufficient power to look at interven-
tion effect on adherence at each cluster. Activity-adjusted
antibiotic sales statistics for broad-spectrum antibiotics pro-
vides however the opportunity to assess change in levels and
trends of broad-spectrum antibiotic use, indicating prescrib-
ing behaviour over longer periods of time.
In our study we found that the context we implemented
interventions in were even more important than the type
of intervention selected. Tailoring the interventions to the
local context and challenges of each study ward and more
focus on using SMART1 goals during the planning and
implementation of interventions, could increase the possi-
bility to get the desired outcomes. LRTIs are common in
stewardship intervention studies [6, 18]. It is a wise place
to start optimization of antibiotic prescribing, because the
volume of patients secures great impact on total antibiotic
use. More severe diagnoses, like infections in immuno-
compromised patients may be a bigger challenge to target
in behaviour change. Especially inexperienced physicians
may feel the need to secure adequate coverage with
broad-spectrum antibiotics at treatment initiation and the
thought of “never change a winning team” may lead to
lack of re-evaluation and focusing treatment [26].
When designing behavioural change interventions in
antibiotic stewardship programs, we need careful plan-
ning. Attention should be paid to local barriers and facili-
tators for change and we should have in-depth knowledge
of local antibiotic prescribing practices and case mix to
guide the focus of interventions.
Conclusions
Pulmonary intervention wards had an increase in adher-
ence, independent of applied intervention, while no effect
was seen at wards of infectious diseases and gastroenter-
ology. This shows that the context in which interventions
are implemented is important and may also indicate that
pulmonary wards may be a good place to start when chan-
ging antibiotic prescribing behavior in similar hospital set-
tings. We also showed that when ward physicians were
actively involved in the process of discussing their own
prescribing behavior and could identify and agree on spe-
cific targets for change in prescribing practice, great
change was achieved within a short timeframe.
Endnotes
1SMART: Specific, Measurable, Attractive, Realistic
and Time-bound
Appendix
Appendix show results for interrupted time series analysis
of the use of broad- spectrum antibiotics for intervention
groups and specialties:





























































































































































































































































































































































































































































































































































































































































































































































































































































Wathne et al. Antimicrobial Resistance and Infection Control  (2018) 7:109 Page 9 of 12
Table 6 Interrupted Time Series analysis of the use of Ciprofloxacin at the ward of Gastroenterology, Hospital A, from 2013 to 2015
Estimate SE p-value
Ciprofloxacin DDD per 100 bed days Constant 10.291 1.283 0.000
AR −0.090 0.520 0.868
Pre-slope −0.169 0.341 0.636
Difference between pre- and post-slope −0.106 0.461 0.825
Level effect
3 months −4.254 1.905 0.061
6 months −4.360 1.956 0.061
12 months −4.571 2.343 0.092
18 months −4.783 2.975 0.152
Use of Ciprofloxacin is measured as quarterly sales of Ciprofloxacin, adjusted for bed days
Fig. 1 Use of broad-spectrum antibiotics at intervention wards and per specialty intervention wards compared to control wards
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Abstract
Background: Clinical antibiotic prescribing guidelines are essential in defining responsible use in the local context.
Our objective was to investigate the association between adherence to national antibiotic prescribing guidelines
and patient outcomes across a wide range of infectious diseases in hospital inpatients.
Methods: Over five months in 2014, inpatients receiving antibiotics under the care of pulmonary medicine,
infectious diseases and gastroenterology specialties across three university hospitals in Western Norway were
included in this observational cohort study. Patient and antibiotic prescribing data gathered from electronic medical
records included indication for antibiotics, microbiology test results, discharge diagnoses, length of stay (LOS),
comorbidity, estimated glomerular filtration rate (eGFR) on admission and patient outcomes (primary: 30-day
mortality; secondary: in-hospital mortality, 30-day readmission and LOS). Antibiotic prescriptions were classified as
adherent or non-adherent to national guidelines according to documented indication for treatment. Patient
outcomes were analysed according to status for adherence to guidelines using multivariate logistic, linear and
competing risk regression analysis with adjustments made for comorbidity, age, sex, indication for treatment,
seasonality and whether the patient was admitted from an institution or not.
Results: In total, 1756 patients were included in the study. 30-day-mortality and in-hospital mortality were lower
(OR = 0.48, p = 0.003 and OR = 0.46, p = 0.001) in the guideline adherent group, compared to the non-adherent
group. Adherence to guideline did not affect 30-day readmission. In linear regression analysis there was a trend
towards shorter LOS when LOS was analysed for patients discharged alive (predicted mean difference − 0.47, 95%
CI (− 1.02, 0.07), p = 0.081). In competing risk analysis of LOS, the adherent group had a subdistribution hazard ratio
(SHR) of 1.17 95% CI (1.02, 1.34), p = 0.025 for discharge compared to the non-adherent group.
Conclusions: Adhering to antibiotic guidelines when treating infections in hospital inpatients was associated with
favourable patient outcomes in terms of mortality and LOS.
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Mortality, Readmission, Length of stay
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Background
Antibiotics constitute an important class of medicines,
where the use of a substance has implications beyond
the patient being treated. Antimicrobial stewardship is a
systematic way to improve antibiotic use in hospitals
and has most recently been defined as “a coherent set of
actions which promote using antimicrobials responsibly”
[1]. Clinical guidelines for antibiotic use are essential in
defining responsible use in the local context and are one
of the core elements of stewardship programmes [2].
Studying the association between antibiotic use and pa-
tient outcomes is of great importance and can imply
whether guideline-adherent prescribing practice is safe
and secures equal – or better patient outcome. Most stud-
ies in this field are performed within lower respiratory
tract infections and many are prone to confounding by in-
dication, because patients with less severe illness are more
likely to have received the more narrow-spectrum, guide-
line adherent therapy [3].
Norway has low, but steadily increasing antibiotic re-
sistance rates [4]. Seven months prior to this study, new
national guidelines for antibiotic use in hospitals were
published [5]. We aimed to investigate if appropriate
prescribing practices for hospitalised patients with a
broad spectrum of infectious diseases were associated
with patient outcomes when adjusted for major con-
founding factors.
Methods
Study design and setting
We performed an observational study in the cohort of
patients from a previously published cluster randomized
controlled intervention study, which was performed at
three emergency care and teaching hospitals in Western
Norway [6]. Hospital A and B are tertiary care hospitals
with 1100 and 600 beds, respectively. Hospital C is a
secondary care hospital with 160 beds. Hospital A is in
addition referral hospital for hospitals B and C. Three
medical wards from hospital A and B (infectious dis-
eases, pulmonary medicine and gastroenterology) and
two medical wards from hospital C (infectious diseases/
general medicine and pulmonary/cardiac medicine) were
included in the study. All hospitals were committed to
be using the national guideline for antibiotic use for hos-
pital inpatients [5].
Data collection
Adult patients (over 18 years old) were included in the
study if they received antibiotics for a suspected or con-
firmed infection during admission, were discharged from
a study ward between the 10th of February and the 11th
of July 2014 and had a hospital stay of > 24 h and ≤ 21
days. Minimum length of hospital stay was defined to
assure that included patients were seen by study ward
physicians and maximum length to make manual data
collection throughout the hospital stay feasible. Patients
who either only received antibiotic prophylaxis, had
orthopaedic prosthesis infections or had an indication
for treatment not covered by the national guidelines,
were not included. For patients readmitted during the
study period, only the first stay was included in analysis.
Where data regarding outcome was not possible to re-
trieve (e.g. tourists), or comorbidity data was unavailable,
the patient was excluded. Data were collected manually
from electronic medical records, including admission
notes, medical charts, physician’s notes, discharge letters
and laboratory results. Data included patient demo-
graphics, indication for antibiotic treatment, antibiotic
use, microbiology test results, estimated glomerular fil-
tration rate (eGFR) on admission, length of stay (LOS),
30-day readmission, in-hospital and 30-day mortality,
comorbidity and admittance from- or discharge to insti-
tution. Mortality data was continuously updated within
the electronic medical record, using data from the Nor-
wegian National Registry [7] Supplementary data on
main diagnosis at discharge and comorbidity was re-
trieved by extraction from electronic medical records.
Readmissions were only captured if patients were re-
admitted to the same hospital as the patient was dis-
charged from.
Definitions
All substances comprising the ATC-group “Antibacte-
rials for systemic use” (J01), metronidazole tablets
(P01AB01) and vancomycin tablets (A07AA09) were in-
cluded in the definition of antibiotics for this study [8].
Outcome measures
Primary outcome measure was 30-day mortality, defined
as all-cause mortality during hospital stay or within 30
days of discharge from hospital.
Secondary outcome measures were
a) In-hospital mortality, defined as all-cause in-
hospital mortality during study admission.
b) 30-day readmission, defined as all-cause acute re-
admission to the same study hospital as the patient
was discharged from, within 30 days of discharge,
for patients discharged alive and not transferred to
another hospital.
c) Length of stay, defined as number of days from
admission to discharge for the entire hospital stay
for patients discharged alive, except for time spent
at a hospital rehabilitation centre after discharge
from a study ward. LOS was also analysed for
all patients, with in-hospital mortality as com-
peting risk.
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Study variable
Adherence to national antibiotic guidelines refers to the
choice of active substance(s) for the initial indication for
treatment. Dosing of the substance(s) was not consid-
ered. Adherence was assessed by using syntax in SPSS,
combining the variable for indication for treatment with
the variable for prescribed treatment. Only the
first-choice empirical regimens were regarded adherent.
For patients with antibiotic allergies or kidney failure
where chosen treatment was an alternative guideline
regimen (not first choice), manual adjustment of the ad-
herence variable was performed consistently throughout
the study population. CRB-65-score1 and the severity of
pneumonia were usually not explicitly stated in the pa-
tient notes. Less severe and severe community acquired
pneumonia were therefore assessed together, meaning
that first line treatments for both conditions were con-
sidered adherent. Some patients had more than one
working diagnosis on initiation of therapy. An
ID-physician (BS) reviewed the diagnoses and decided
indication for treatment for these patients, expecting ini-
tial therapy to be based on the most severe working
diagnosis. Infections described as “suspected pneumo-
nia” or “unspecified lower respiratory tract infection” on
admission were assessed for adherence as community-
or hospital acquired pneumonia. A working diagnosis as
“suspected urinary tract infection” (UTI) was assessed as
adherent if treatment was according to guideline treat-
ment for either pyelonephritis or cystitis. For the indica-
tion “suspected pneumonia/UTI”, treatment according
to guideline recommendation for either diagnosis were
considered adherent.
Adjustment variables
Indication for treatment was the indication for first
treatment with antibiotics and was always an infection.
Physicians’ notes were used to identify indication for
treatment and indication was not further assessed for
validity. Indications were grouped into six main categor-
ies (Table 1). Indications which did not fit into the main
categories were included in a seventh category of “Other
infections”. Empirical antibiotic treatment was specific
for each indication and varied within each group.
Comorbidity was defined using the Charlson Comor-
bidity Index (CCI) [9, 10]. For each patient, up to eight
diagnoses were extracted from the hospital electronic
medical record at discharge. All extracted diagnoses
were included in the calculation of CCI, using Stata syn-
tax [11]. Estimated glomerular filtration rate on admis-
sion was originally planned as an adjustment variable,
but as renal disease is included in CCI, this was dis-
carded from analysis. Age was coded in age groups,
starting with patients up to and including the age of
45 and thereafter given in groups of 20 years to the
last group of above 85 years. Admission from an in-
stitution was defined as patients admitted at an in-
stitution with 24/7 care, e.g. another hospital or
nursing home, within 48 h of admission. Adjustment
for seasonality was performed by using the week of
admission as adjustment variable.
Statistics/analysis
To analyse differences in patient characteristics between
the groups with adherent and non-adherent treatment,
we used chi-square test and two-sample t-test for cat-
egorical and continuous data, respectively. Univariate
and multivariate logistic and linear regression were used
to study the association between guideline adherent pre-
scribing practice and patient outcome. Indication for
treatment, comorbidity (CCI), age group, admittance
from institution, sex and seasonality (week of admission)
were evaluated as adjustment variables. Variables that in
univariate regression analysis of 30-day mortality had a
p-value of less than 0.2 (all evaluated variables) were in-
cluded in multivariate analyses for all studied outcomes.
In addition, we used robust variance estimation of re-
gression coefficients to account for clustered observa-
tions on the same hospital ward.
Two sensitivity analyses were performed for 30-day
mortality. In the first, grouping of indication for treatment
was replaced by grouped discharge diagnoses as adjust-
ment variable to evaluate whether estimates of association
would change if diagnoses had changed from admission to
discharge. In the second sensitivity analysis, grouping of
indication for treatment was replaced by individual indica-
tions as an adjustment variable to evaluate whether the
grouping of indications could influence the results.
As the linear regression models of LOS did not ac-
count for in-hospital mortality, we also performed a sen-
sitivity analyses for this outcome by fitting a Fine-Gray
model with in-hospital mortality as competing risk. In
this analysis, we report associations as the subdistribu-
tion hazard ratio (SHR) with 95% confidence intervals,
which denotes the magnitude of the relative difference
in the subdistribution hazard function between adherent
and non-adherent groups [12].
A p-value of < 0.05 was considered statistically signifi-
cant for all analyses. Statistical analysis was performed
using Stata SE version 15 (Stata Statistical Software,
College Station, TX, USA).
Results
During the study period, 1783 patients were eligible for
inclusion. We were not able to retrieve comorbidity data
for 22 patients. For 5 patients who were tourists, out-
come data was unavailable. In final analyses, 1756 pa-
tients were therefore included.
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There was a significant difference between the adher-
ent and non-adherent group with regards to the groups
of indication for treatment, with a higher percentage of
LRTI’s in the adherent group and more patients with
GI-infections, UTIs and “other” infections in the
non-adherent group (Table 2). The non-adherent group
also had a higher proportion of patients admitted from
an institution.
Thirty-day mortality and in-hospital mortality was
significantly lower in patients receiving guideline adher-
ent treatment, with an odds ratio (OR) of 0.48, with p =
0.003 for 30-day mortality and OR = 0.46, with p = 0.001
for in-hospital mortality (Table 3).
During admission, 70 patients died and 16 patients
were discharged to another hospital, so in analysis of
30-day readmission and LOS, 1670 patients were in-
cluded (Table 4). There was no evidence of any dif-
ferences in 30-day readmission between patients
receiving guideline adherent treatment or not. Co-
morbidity (CCI) and seasonality (the week of admis-
sion) were the only variables significantly associated
with 30-day readmission. In the linear regression
analysis of LOS, there was a trend towards shorter
LOS when guideline adherent treatment was pre-
scribed at treatment onset (− 0.47 days, p = 0.087)
(Table 4). This result was supported by the compet-
ing risk analyses of LOS in which the adherent
group was associated with a 17% increase in the rate
of discharge, compared with the non-adherent group
(Additional file 1: Table S1; SHR 1.17, 95% CI (1.02,
1.34), p = 0.025).
Other analysis
We performed two sensitivity analyses for 30-day mor-
tality. In the first analysis, grouped indications for
treatment were substituted with grouped discharge diag-
noses, which could be infections or non-infections. The
association between adherent treatment and mortality now
had an OR= 0.51, 95% CI (0.33, 0.80) with p = 0.003 (not
shown in tables). In the second analysis, grouped indica-
tions were substituted with the individual indications in the
regression model. This changed the estimated OR from
0.48 to 0.54, 95% CI (0.30, 0.99), p = 0.045 (not shown in
tables). For the last analysis, model fit was poor for indica-
tions with few patients and no observed mortality. Only
1591 patients were kept in the model for this analysis.
Discussion
The main findings of this study are that adherence to
antibiotic guidelines at initiation of antibiotic therapy is
associated with lower in-hospital- and 30-day mortality
and shorter LOS. Adherence to guidelines was not sig-
nificantly associated with 30-day readmission.
Structure and process indicators can help us evaluate
whether our antibiotic stewardship efforts are moving us
in the right direction [13–16]. A frequently asked ques-
tion is whether behavioural change interventions lead to
more appropriate antibiotic use, often measured as ad-
herence to guidelines or profile of antibiotic consump-
tion [3, 6, 17]. An equally important question is whether
appropriate antibiotic use leads to the desired outcomes,
like reduction in bacterial resistance rates, adverse
events and mortality [3, 18]. Overprescribing outside
guidelines often result from fear for the patients’ well-
being, and are linked to patients who are severely ill or
have an unclear diagnosis [19]. The expectation of clini-
cians’ to change their antibiotic prescribing behaviours
needs to be supported by evidence-based guidelines and
expert advice to reassure clinicians that guideline adher-
ent antibiotic prescribing is safe and effective.
Table 1 Grouping of indications for treatment
Indication for treatment
Lower respiratory tract infections (LRTI) Community acquired pneumonia (normal and severe), healthcare associated pneumonia (normal
and severe), unspecified lower respiratory tract infections, unknown – suspected pneumonia,
aspiration pneumonia, atypical pneumonia, lung abscess, empyema.
Acute exacerbations of chronic obstructive
pulmonary disease (COPD with LRTI)
Patients with COPD, presenting with LRTI (community and healthcare associated)
Sepsis Focus area; lower respiratory tract, urinary tract, unknown focus, soft tissue, abdomen
and catheter.
Skin and soft tissue infections (SSTI) Erysipelas, cellulitis, abscess, other skin and soft tissue infections, mastitis, necrotising soft tissue
infections, postoperative wound infection.
Gastrointestinal tract infections (GI-infections) Helicobacter pylori-infection, gastroenteritis, peritonitis, cholecystitis/cholangitis, Clostridium
difficile (C.Diff).
Urinary tract infections (UTI) UTI – unspecified, pyelonephritis, lower UTI/cystitis, unknown-suspected UTI, catheter
associated UTI.
Other infections Suspected both pneumonia and UTI, meningitis, neutropenic fever, osteomyelitis, tonsillitis,
arthritis, endocarditis, sinusitis/otitis, and infected intravascular catheters
Indications within each group are given in decreasing order of frequency
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Readmission as an outcome measure in relation to
antibiotic prescribing is not frequently reported [18].
Three studies within community acquired pneumonia
show no association between guideline adherence and
30-day readmission, which is in agreement with the find-
ings in this present study [20–22].
Evidence on the association between guideline
adherence and mortality is diverse. Arnold et al. found
that in-hospital mortality in patients receiving
guideline-adherent treatment for community acquired
pneumonia was 8% (95% CI, 7–10%), compared to 17%
(95% CI, 14–20%) in the group of nonadherence [23].
Asadi et al. did not find any effect on mortality
alone when looking at this variable in hospitalised
patients with community acquired pneumonia,
although the composite endpoint of death or
ICU-admissions favoured guideline adherence [24].
In a Danish study of CAP, with similar resistance
rates and treatment guidelines as Norway, Egelund
et al. found that patients treated with guideline ad-
herent penicillin monotherapy had lower CURB-65
score, less comorbidity and less in-hospital mortality
in unadjusted analysis, while no association between
mortality and guideline adherence was found in
Table 2 Patient characteristics and outcome by adherence or non-adherence to guidelines
Non-adherence (N = 667) Adherence (N = 1089) P-value
Patient characteristics
Indication for treatment
LRTI 161 (24.1) 372 (34.2) < 0.001
COPD with LRTI 124 (18.6) 230 (21.1)
Sepsis 111 (16.6) 180 (16.5)
SSTI 72 (10.8) 115 (10.6)
GI-infection 44 (6.6) 34 (3.1)
UTI 80 (12.0) 99 (9.1)
Other infections 75 (11.2) 59 (5.4)
Charlson Comorbidity Index
CCI = 0 240 (36.0) 432 (39.7) 0.083
CCI = 1 212 (31.8) 373 (34.3)
CCI = 2 119 (17.8) 141 (13.0)
CCI = 3 45 (6.8) 65 (6.0)
CCI = 4 24 (3.6) 33 (3.0)
CCI > 4 27 (4.1) 45 (4.1)
Age, mean (std.dev.) 67.3 (18.2) 67.4 (19.1) 0.885
Age
<=45 92 (13.8) 161 (14.8) 0.680
46–65 156 (23.4) 240 (22.0)
66–85 320 (48.0) 508 (46.7)
>85 99 (14.8) 180 (16.5)
Admitted from institution 120 (18.0) 135 (12.4) 0.001
Discharged to institution 182 (29.0) 258 (24.4) 0.090
Sex
Male 352 (52.8) 565 (51.9) 0.717
Female 315 (47.2) 524 (48.1)
Outcome
In-hospital mortality 38 (5.7) 32 (2.9) 0.004
30-day mortality 75 (11.2) 67 (6.2) < 0.001
30-day readmission (n = 623/1047) 140 (22.5) 206 (19.7) 0.173
LOSa, mean (std.dev.) (n = 623/1047) 7.3 (4.4) 6.7 (4.1) 0.004
aLOS = Length of stay. All analysis was performed using chi-square tests, except mean age and LOS which were analysed using two-sample t-test. P-values in
boldface are statistically significant (<0.05)
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adjusted analysis [25]. However, a systematic review
by Schuts et al., including 37 studies, showed that
when empirical therapy was prescribed according to
guidelines, the relative risk reduction of mortality
was 35% [18]. The majority of patients included in
these studies had pulmonary infections. These pa-
tients constituted almost half of our patient mater-
ial. Our findings are coherent with this recent
review, as we found that the odds ratio of
in-hospital and 30-day mortality for the entire
patient material was 0.46 and 0.48, respectively
when guidelines were followed.
LOS was also favourably associated with adherent
treatment in this study. The SHR was 1.17 for pa-
tients with guideline-adherent treatment, meaning
that the rate of discharge was 17% higher for this
group compared to the rate for the non-adherent
group. Although not significant, there was a trend to-
wards shorter LOS when analysed with linear regres-
sion analysis. 0.47 days constitutes 6.8% of the mean
Table 3 Adjusted analysis of the association between guideline adherence, in-hospital and 30-day mortality
All patients In-hospital mortality 30-day mortality
(N = 1756) (n1 = 70) (N = 1756) P (n2 = 142) (N = 1756) P
n (%) n (%) OR (95% CI) n (%) OR (95% CI)
Adherence to guideline
No 667 (38.0) 38 (5.7) 1.00 75 (11.2) 1.00
Yes 1089 (62.0) 32 (2.9) 0.46 (0.29, 0.74) 0.001 67 (6.2) 0.48 (0.29, 0.78) 0.003
Indication for antibiotic treatment
LRTI 533 (30.4) 35 (6.6) 1.00 69 (13.0) 1.00
COPD with LRTI 354 (20.2) 11 (3.1) 0.44 (0.22, 0.86) 0.017 22 (6.2) 0.45 (0.35, 0.59) < 0.001
Sepsis 291 (16.6) 14 (4.8) 0.69 (0.41, 1.15) 0.153 24 (8.3) 0.59 (0.36, 0.97) 0.038
SSTI 187 (10.7) 1 (0.5) 0.12 (0.02, 0.66) 0.015 3 (1.6) 0.17 (0.03, 1.09) 0.061
GI-infection 78 (4.4) 3 (3.9) 0.75 (0.10, 5.72) 0.782 6 (7.7) 0.78 (0.22, 2.80) 0.708
UTI 179 (10.2) 2 (1.1) 0.12 (0.27, 0.55) 0.006 11 (6.2) 0.35 (0.19, 0.63) 0.001
Other infections 134 (7.6) 4 (3.0) 0.35 (0.17, 0.72) 0.004 7 (5.2) 0.29 (0.19, 0.46) < 0.001
Charlson Comorbidity Index
CCI = 0 672 (38.3) 9 (1.3) 1.00 20 (3.0) 1.00
CCI = 1 585 (33.3) 19 (3.3) 1.60 (0.52, 4.86) 0.411 36 (6.2) 1.40 (0.95, 2.04) 0.088
CCI = 2 260 (14.8) 16 (6.2) 2.66 (0.72, 9.83) 0.143 31 (11.9) 2.67 (1.45, 4.90) 0.002
CCI = 3 110 (6.3) 6 (5.5) 2.27 (0.60, 8.60) 0.228 16 (14.6) 3.18 (1.75, 5.78) < 0.001
CCI = 4 57 (3.3) 8 (14.0) 6.39 (1.64, 24.93) 0.008 14 (24.6) 6.79 (3.31, 13.95) < 0.001
CCI > 4 72 (4.1) 12 (16.7) 8.50 (3.80, 19.04) < 0.001 25 (34.7) 12.04 (8.02, 18.08) < 0.001
Age
< =45 253 (14.4) 1 (0.4) 1.00 2 (0.8) 1.00
46–65 396 (22.6) 7 (1.8) 2.35 (0.35, 15.70) 0.376 14 (3.5) 2.40 (0.53, 10.87) 0.257
66–85 828 (47.2) 39 (4.7) 5.42 (0.82, 35.67) 0.079 80 (9.7) 5.61 (1.51, 20.85) 0.010
> 85 279 (15.9) 23 (8.2) 10.13 (0.99, 103.78) 0.051 46 (16.5) 9.81 (1.91, 50.36) 0.006
Admitted from institution
No 1501 (85.5) 46 (3.1) 1.00 88 (5.9) 1.00
Yes 255 (14.5) 24 (9.4) 2.53 (1.45, 4.43) 0.001 54 (21.2) 3.74 (2.69, 5.20) < 0.001
Sex
Male 917 (52.2) 49 (5.3) 1.00 88 (9.6) 1.00
Female 839 (47.8) 21 (2.5) 0.42 (0.28, 0.61) < 0.001 54 (6.4) 0.59 (0.39, 0.90) 0.015
Week of admissiona 0.96 (0.93, 0.99) 0.005 0.96 (0.93, 0.997) 0.031
aAdjustment for seasonality was performed by using the week of admission as adjustment variable
In-hospital – and 30-day mortality was analysed using multivariate, logistic regression analysis with adjustment for clustering at individual sites. All variables are
included in adjusted analysis. P-values in boldface are statistically significant (<0.05)
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LOS for the study population (6.9 days) and 10.9% of
a mean hospital stay in Norway, which is currently
4.3 days for patients outside the psychiatric wards
[26]. The finding is in line with Schuts et al. which
found that LOS was lower in 17 of the 24 included
studies assessing association between adherence to
guideline and LOS, favouring adherence [18]. The
studies included in this review did however mainly in-
clude patients with lower respiratory tract infections,
while our cohort had a large diversity of infectious
diseases, and a maximum LOS of 21 days.
In observational cohort studies, the major limitation
will be the potential for selection bias, in this case
meaning that the patients with less severe illness may
be more likely to receive guideline-adherent treatment
[3]. By adjusting for indication for treatment, comor-
bidity, age, sex and seasonality, we have aimed to re-
duce the chance of confounding, but there could be
differences in severity within each of the groups of
indications, which could explain some of the differ-
ence seen in mortality between the adherent and
non-adherent group. We did not have data on
Table 4 Adjusted analysis of the association between guideline adherence, 30-day readmission and length of stay
All patients 30 day readmission Length of stay
(N = 1670) (N = 346) (N = 1670) P (N = 1670) (N = 1670) P
n (%) n (%) OR (95%CI) Mean (S.D) Coeff. (95% C.I.)
Adherence to guideline
No 623 (37.3) 140 (22.5) 1.00 7.3 (4.4)
Yes 1047 (62.7) 206 (19.7) 0.87 (0.67, 1.14) 0.321 6.7 (4.1) −0.47 (−1.02, 0.07) 0.081
Indication for antibiotic treatment
LRTI 492 (29.5) 100 (20.3) 1.00 7.0 (4.3)
COPD with LRTI 341 (20.4) 88 (25.8) 1.17 (0.80, 1.73) 0.421 6.6 (3.8) −0.79 (−1.65, 0.08) 0.069
Sepsis 275 (16.5) 46 (16.7) 0.81 (0.54, 1.21) 0.303 7.0 (3.9) 0.22 (−0.73, 1.18) 0.605
SSTI 184 (11.0) 29 (15.8) 0.89 (0.62, 1.28) 0.522 6.2 (4.1) −0.17 (−1.44, 1.10) 0.761
GI-infection 75 (4.5) 18 (24.0) 1.26 (0.64, 2.51) 0.503 7.3 (4.2) 0.53 (− 0.75, 1.81) 0.363
UTI 176 (10.5) 43 (24.4) 1.30 (0.85, 2.01) 0.229 7.1 (4.4) 0.10 (−0.74, 0.95) 0.781
Other infections 127 (7.6) 22 (17.3) 0.78 (0.51, 1.18) 0.240 7.5 (5.1) 0.53 (−0.83, 1.89) 0.386
Charlson Comorbidity Index
CCI = 0 656 (39.3) 97 (14.8) 1.00 6.3 (3.9)
CCI = 1 562 (33.7) 117 (20.8) 1.35 (1.03, 1.76) 0.029 6.9 (4.0) 0.60 (−0.32, 1.53) 0.168
CCI = 2 241 (14.4) 73 (30.3) 2.26 (1.46, 3.52) < 0.001 7.3 (4.2) 0.87 (0.06, 1.68) 0.039
CCI = 3 103 (6.2) 27 (26.2) 1.77 (1.12, 2.82) 0.015 7.7 (5.0) 1.30 (−0.79, 3.38) 0.185
CCI = 4 49 (2.9) 16 (32.7) 2.55 (1.73, 3.76) < 0.001 9.1 (5.4) 2.64 (− 0.42, 5.70) 0.081
CCI > 4 59 (3.5) 16 (27.1) 1.88 (0.89, 3.95) 0.098 9.1 (5.2) 2.42 (1.15, 3.69) 0.003
Age
< =45 250 (15.0) 37 (14.8) 1.00 5.7 (4.1)
46–65 387 (23.2) 75 (19.4) 1.07 (0.71, 1.62) 0.743 6.6 (4.0) 0.74 (0.45, 1.03) 0.001
66–85 779 (46.7) 175 (22.5) 1.15 (0.70, 1.90) 0.576 7.3 (4.3) 1.20 (0.58, 1.83) 0.002
> 85 254 (15.2) 59 (23.2) 1.24 (0.62, 2.49) 0.549 7.2 (4.3) 1.00 (−0.19, 2.18) 0.087
Sex
Male 856 (51.3) 182 (21.3) 1.00 6.9 (4.3)
Female 814 (48.7) 164 (20.2) 0.94 (0.81, 1.09) 0.411 6.9 (4.1) 0.02 (−0.64, 0.69) 0.942
Admitted from institution
No 1441 (86.3) 301 (20.9) 1.00 6.8 (4.2)
Yes 229 (13.7) 45 (19.7) 0.85 (0.62, 1.16) 0.307 7.2 (4.5) 0.02 (−0.53, 0.57) 0.938
Week of admissiona 0.98 (0.96, 1.00) 0.040 −0.05 (− 0.09, − 0.002) 0.044
aAdjustment for seasonality was performed by using the week of admission as adjustment variable
All variables are included in adjusted analysis. 30-day readmission and length of stay was analysed using multivariate logistic- and linear regression, respectively
with adjustment for clustering at individual sites. P-values in boldface are statistically significant (<0.05)
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severity score, which could have helped us limit this
factor. The grouping of indications is both a strength
and a limitation. Looking at patient outcome and ad-
herence across some of the most common infections
seen in hospitals, makes the results more
generalizable, but may also be more difficult to inter-
pret. When working diagnosis on initiation of treat-
ment was uncertain (eg “suspected UTI”) or there
were more than one working diagnoses, we assessed
adherence based on the most likely indication for
treatment. Using working diagnoses for this purpose
is limiting the generalizability of the results to indi-
vidual groups of patients with more strict definitions
of diagnoses. It does however reflect the daily chal-
lenge in the clinical setting where decisions about
treatment have to be made before all diagnostic tools
have been applied and results received and indicates
that adhering to the most relevant guideline is a
strength in this situation.
There were more patients admitted from an institution in
the non-adherent group. This may be because patients ad-
mitted from institutions have more co-morbid disease and
therefore present with more challenging diagnoses. Physi-
cians may also consider the risk of resistant pathogens as
higher and therefore prescribe more broad-spectrum
agents. Furthermore, patients admitted from other institu-
tions may already have received first line agents. Patient
characteristics such as age, sex and comorbidity were very
similar between the groups of patients receiving adherent
or non-adherent treatment according to guidelines. The
groups of UTI’s, “other” infections and GI-infections were
however larger in the non-adherent group and LRTIs were
larger in the adherent group. Prescribing for pneumonia
and COPD exacerbations was the focus of the audit with
feedback performed in the study wards in the underlying
intervention study [6]. The mix of patients within the
groups of indications varied to some extent, such as a
higher number of pyelonephritis in the non-adherent group
(38.8%) compared to the adherent group (23.2%) and
higher number of sepsis with abdominal focus in
non-adherent group (4.5%) compared to adherent group
(0.6%). In a sensitivity analysis for 30-day mortality, the
grouped indications were substituted with the individual in-
dications. This only changed the estimated OR slightly, to
0.53. The difference seen between the groups can therefore
not be explained by these factors alone. Another mechan-
ism is of course that treatment recommended in guidelines
is best practice - securing evidence based effective treat-
ment of the infection, while minimizing ecologic effects,
side effects and impact on the microbiotia and therefore is
associated with better patient outcomes than non-adherent
treatment.
We analysed according to the first indication for
treatment, which was usually a working diagnosis on
admission to the hospital. The diagnosis may have
changed during the hospital stay. We therefore did a
sensitivity analysis for 30-day mortality, where indica-
tion for treatment was substituted with discharge
diagnosis. The OR for the association between adher-
ent treatment and mortality only changed slightly,
from 0.48 to 0.51.
Thirty-day readmission was defined as readmissions to
the same hospital that the patient was discharged from.
This could have caused an underestimation of readmis-
sions if the patients were readmitted to other hospitals.
As inclusion of patients were limited to a LOS of a max-
imum of 21 days, the mean LOS may be underestimated.
Adherence to guideline within the group of excluded pa-
tients was not collected and is therefore unknown.
This was a multicentre study with patients included
from three hospitals and three specialties, which in-
creases generalizability. The number of included patients
is also substantial and we adjusted for known risk factors
for morbidity and mortality, such as age, comorbidity
and admittance from an institution. Given that patients
with a LOS longer than 21 days were excluded, this
limits generalizability of the estimate for this outcome.
Norwegian guidelines were developed with broad
involvement of more than 80 clinicians from all over the
country [5, 27]. They are prudent, with mainly
narrow-spectrum antibiotics as first-line empirical treat-
ment [5]. It is of great importance that guidelines consti-
tute best practice, to provide security for both the
patient and the treating clinician, and secures standard-
ized, safe and effective antibiotic treatment, also in the
absence of an infectious diseases specialist.
This study builds on findings in previous studies, indi-
cating that up-to-date, hospital antibiotic guidelines are
safe and are associated with favourable clinical outcomes
for inpatients. Antibiotic guidelines should be developed
and regularly updated to ensure that they always pro-
mote best practice in the treatment of infectious diseases
in the local context. Accurate, structured and
easy-to-access documentation on severity of infections
should be included in the electronic medical record to
secure availability of this data in quality improvement
processes, evaluation of treatment and research.
To be able to control for more factors in analyses, fu-
ture studies should aim to collect information about se-
verity of infections and whether empirical treatment
provided adequate coverage for the individual patients.
Conclusion
Empirical treatment according to guidelines on initiation
of antibiotic therapy is associated with favourable clinical
outcomes, such as in-hospital and 30-day mortality in
our population of hospital inpatients.
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Endnotes
1CRB-65 (Severity assessment for pneumonia: Confu-
sion, raised Respiratory rate, low Blood pressure and age
65 years or more).
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Identifying targets for antibiotic stewardship interventions through analysis of the antibiotic 
prescribing process in hospitals - a multicentre observational cohort study 
Abstract 
Background: In order to change antibiotic prescribing behaviour, we need to understand the 
prescribing process. The aim of this study was to identify targets for antibiotic stewardship 
interventions in hospitals through analysis of the antibiotic prescribing process from admission to 
discharge across five groups of infectious diseases.  
Methods: We conducted a multi-centre, observational cohort study, including patients with lower 
respiratory tract infections, exacerbation of chronic obstructive pulmonary disease, skin- and soft 
tissue infections, urinary tract infections or sepsis, admitted to wards of infectious diseases, pulmonary 
medicine and gastroenterology at three teaching hospitals in Western Norway. Data was collected 
over a 5-month period and included antibiotics prescribed and administered during admission, 
antibiotics prescribed at discharge, length of antibiotic therapy, indication for treatment and discharge 
diagnoses, estimated glomerular filtration rate (eGFR) on admission, antibiotic allergies,  place of 
initiation of therapy, admittance from an institution, patient demographics and outcome data. Primary 
outcome measure was antibiotic use throughout the hospital stay, analysed by WHO AWaRe-
categories and adherence to guideline. Secondary outcome measures were a) antibiotic prescribing 
patterns by groups of diagnoses, which were analysed using descriptive statistics and b) non-
adherence to the national antibiotic guidelines, analysed using multivariable logistic regression.  
 
Results: Through analysis of 1235 patient admissions, we identified five key targets for antibiotic 
stewardship interventions in our population of hospital inpatients;  1) adherence to guideline on 
initiation of treatment, as this increases the use of WHO Access-group antibiotics, 2) antibiotic 
prescribing in the emergency room (ER), as 83.6% of antibiotic therapy was initiated there,  3) 
prescribing for patients admitted from other institutions, as this was significantly associated with 
non-adherence to guideline (OR=1.44 95% CI 1.04, 2.00),  4) understanding cultural and contextual 
drives of antibiotic prescribing, as non-adherent prescribing differed significantly between the sites 
of initiation of therapy (between hospitals and ER versus ward) and 5) length of therapy, as days of 
antibiotic therapy was similar across a wide range of diagnoses and with prolonged therapy after 
discharge.   
 
Conclusions: Analysing the process of antibiotic prescribing in hospitals with patient-level data 





 Suboptimal use of antibiotics is a key driver of antibiotic resistance [1]. In order to improve the 
antibiotic prescribing process, we need to understand it. Historically, antibiotic sales statistics have 
been easy to collect, and are therefore widely used as a proxy indicator to monitor antibiotic 
prescribing [2-5].  Although analyses of antibiotic sales data are useful at an aggregated level, they do 
not specify patient level use or outcomes. Whilst providing a baseline, such data cannot be used to 
assess the appropriateness of antibiotic prescribing, limiting opportunities for optimising antibiotic 
stewardship interventions. Accurate, patient level assessment of antibiotic prescribing is an essential 
step in optimising antibiotic use.  Audit and prevalence studies with manual data collection are time-
consuming, but often necessary to retrieve this information.  Many hospitals still lack electronic 
medical records that allow automated extraction of antibiotic prescription data with accompanying 
indications for treatment [6-8].  The introduction of WHO Access, Watch and Reserve (AWaRe) 
categories have provided a framework for analysing antibiotic consumption, focusing on limiting 
unnecessary use of watch and reserve antibiotics [9, 10]. We present the findings of an observational 
multicentre cohort study aiming to identify targets for antibiotic stewardship interventions by 
analysing the antibiotic prescribing process from admission to discharge for individual patients. 
 
Methods: 
Study design and setting 
 
This was an observational, multicentre cohort study across the wards of infectious diseases, pulmonary 
medicine and gastroenterology at three teaching hospitals in Western Norway [11]. The largest 
hospitals (denoted A and B hereafter) are emergency care, university hospitals with 1100 and 600 beds, 
respectively, covering most specialities, except transplant surgery. Hospital C is an emergency care, 





The cohort included patients recruited to an antibiotic stewardship intervention study and consisted 
of adult patients discharged from study wards between the 10th of February and the 11th of July 2014 
with a hospital stay ≥ 24 hours and ≤ 21 days, receiving antibiotics during admission for an indication 
within guideline recommendations [11, 12]. If a patient was readmitted during the study period, only 
the first stay was included. Patients with the following indications were included in the analysis: 1) 
lower respiratory tract infections (LRTI) 2) exacerbation of Chronic Obstructive Pulmonary Disease 
(COPD ex) 3) urinary tract infections (UTI) 4) skin- and soft tissue infections (SSTI) and 5) sepsis. Patients 
were excluded if: a) they were admitted to intervention wards in the post-intervention period; and b) 
comorbidity and patient outcome data were missing.  
 
Data were collected manually from electronic medical records, including admission notes from the 
emergency room, medical charts, physicians’ clinical notes, discharge letters and laboratory test 
results. Data included patient demographics, indication for antibiotic treatment, antibiotic use 
throughout the hospital stay, discharge diagnoses, estimated glomerular filtration rate (eGFR) on 
admission, length of stay, 30-day readmission, in-hospital and 30-day mortality, comorbidity and 
admittance from institution. Coded data on discharge diagnoses were retrieved from the hospital 
administrative system.  
 
Outcomes 
The primary outcome measure was antibiotic regimens used throughout the hospital stay, grouped by 
AWaRe-categories and guidelines adherence on initiation of treatment and analysed at initiation of 
treatment, after first modification of regimen, and at discharge. Secondary outcome measures were 
antibiotic prescribing patterns by groups of diagnoses and non-adherence to the national antibiotic 




Patient characteristics and diagnoses 
To assess comorbidity, the Charlson Comorbidity Index (CCI) was calculated based on ICD-10 diagnoses 
at discharge [13, 14]. CCI was categorised as CCI equal to 0, 1, 2, 3, 4 or >4, with zero being no registered 
comorbidity and >4 substantial comorbidity. 
 
The initial working diagnosis, documented in the electronic medical record for prescribed antibiotics, 
was used as the principal indication. Patients and treatment regimens were grouped by indications 
according to Supplement 1, Table 1. For patients having several diagnoses, all diagnoses were 
documented and a variable indicating multiple working diagnosis was created.  Co-author BS 
(Infectious diseases (ID)-physician) assessed patients with multiple working diagnoses and assigned a 
primary indication for treatment based on the expectation that the treating physicians were likely to 
choose antibiotic treatment covering the most severe working diagnosis. Accuracy of diagnoses was 
defined as the percentage of patients for whom the initial indication for antibiotic treatment matched 
the discharge diagnosis (group level), defined as the infectious disease diagnosis coded or written in 
free text in the discharge letter.  
 
Antibiotic prescribing 
Antibiotic regimens could include single or multiple antibiotics. Initially prescribed antibiotic regimens 
were assessed for adherence according to the Norwegian national antibiotic guidelines, as all hospitals 
included the national guidelines in their local antibiotic policy. Only first-choice empirical regimen for 
a given indication was regarded adherent. Assessment of adherence was performed using automated 
syntax in SPSS for Windows (IBM SPSS Statistics, version 24, USA). Indication for treatment was 
combined with prescribed active substance(s) to generate the adherence variable and adherence was 




Anti-infectives for systemic use (ATC-group J01), metronidazole tablets (ATC code P01AB01) and 
vancomycin tablets (A07AA09) were defined as antibiotics in this study. The prescribed antibiotic 
regimens were assigned to WHO AWaRe categories [9, 15]. For overview of AWaRe categories and 
included antibiotics, see Supplement 1, Table 2. Antibiotics belonging only to the “key access” category 
were included in the “access” category, while antibiotics belonging to “access-watch” and “watch” 
were included in the watch category. Since the use of antibiotics in the “reserve” category was 
minimal, the groups of “watch” and “reserve” were combined for analysis.  Several antibiotics 
frequently used in Norway are not included in WHO AWaRe categories. To be able to include these 
patients in analysis, a modified version of AWaRe categories was prepared (Supplement 1, Table 2). Of 
the antibiotics not included in the original AWaRe categories, mecillinam, pivmecillinam, metenamin 
and tobramycin were added to the “access” category and cefuroxime was added to the “watch” 
category. If an antibiotic regimen contained both access and watch/reserve-group antibiotics, the 
regimen was classified as watch/reserve.  
 
Modification of antibiotic therapy 
Modifications that prescribing physicians made to the first antibiotic regimen were defined in four 
categories: escalation, de-escalation, change within same level or unchanged. Day 1 was the day 
antibiotic therapy was initiated. Patients with regimens in the unchanged category were not included 
in analysis of time to change.  Definitions of modifications are given in Table 1. Assessment of 
antimicrobial spectrum and categorisation of change were performed and checked by ID-physicians 








Table 1: Modifications of antibiotic regimens 
Process measures Definition 
  
Modification of therapy  
   Escalation Change from oral to intravenous (i.v.) antibiotic treatment within the same 
antibacterial spectrum, change to more broad-spectrum treatment, adding 
an antibiotic to a combination. 
  De-escalation Change from i.v. to oral antibiotic treatment within the same antibacterial 
spectrum or change to more narrow-spectrum treatment. 
   Change same level Change to a regimen within the same antibacterial spectrum and form of 
administration (i.v./oral). 
   Unchanged Regimens where first change of therapy was discontinuation of antibiotics, 
either during admission or after discharge. 
  
Time to first modification of AB 
regimen 
Time to first escalation/de-escalation/change within same antibacterial 
spectrum and dosage form (change of active substance(s), i.v. to oral 
switch, stopping or adding an antibiotic). 
  
Number of treatment regimens The number of treatment regimens from initiation of treatment until 
antibiotics prescribed at discharge 
  
Day of oral antibiotics The first day that one or more oral antibiotics were given. 
 
Duration of antibiotic therapy  
Duration of antibiotic therapy was measured in days from the first to the last day of therapy and 
reported as: 1) mean total days of treatment, including prescribed treatment after discharge, 2) mean 
days of in-hospital antibiotic therapy and 3) mean days of therapy after discharge. When antibiotic 
treatment continued after discharge, the day of discharge was counted as in-hospital therapy. 
Information about antibiotic therapy after discharge was retrieved from the discharge letter and also 
reported as percentage of patients where post-discharge antibiotics were described.  
 
Data analysis  
Descriptive statistics were applied to describe the prescription patterns. To examine which factors 
were associated with non-adherence, we used univariable and multivariable logistic regression. A 
targeted selection of factors were evaluated for the multivariable logistic regression model:  place of  
antibiotic therapy initiation, indication for treatment, hospital site, admission from institution, 
accuracy between indication for treatment and discharge infection diagnosis, sex, age group, 
7 
 
comorbidity measured by CCI, multiple working diagnoses, antibiotic allergies and eGFR. Variables that 
in univariable analysis had a p-value of less than 0.2 were included in the final model. Only the first 
four variables were associated with non-adherence in univariable analysis and included in the final 
multivariable model. P-values below 0.05 were considered statistically significant for all analysis. Stata 
SE version 15 (Stata Statistical Software, College Station, TX, USA) was used for all statistical analysis, 
while SPSS for Windows (IBM SPSS Statistics, version 24, USA) was used for assessment of adherence.  
 
Results 
During the study period, 1544 patients with available comorbidity and outcome data met inclusion 
criteria. Of these patients, 309 were admitted in the post-intervention period at intervention wards 
and was therefore excluded, leaving 1235 unique patients included in analysis for this study.  
 
Diagnoses and patient characteristics 
The characteristics of the patients are given in Table 2. The most frequent diagnosis was LRTI (33.4%), 
followed by COPD exacerbations (22.7%), sepsis (20.1%), SSTI (12.2%) and UTI (11.7%) (not shown in 
tables). In the group of patients with SSTI, 6.0 % of patients were admitted from an institution, 
compared to 20.7% for patients with UTI. When investigating accuracy between the groups of 
indications for empirical antibiotic treatment and discharge infection diagnoses, there was substantial 
variation with a range from 41.5% accuracy for patients initially diagnosed with sepsis, to 95.3% for 




Empirical antibiotic prescribing  
Prescribed antibiotic regimens were adherent to guidelines for 63% of patients (Table 3). Antibiotics 
belonging to the WHO AWaRe “Access” category were prescribed as initial regimen for 74% of patients 
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in total, while the remaining 26.0% of antibiotic regimens were from the “Watch/Reserve” category. 
Where initial antibiotic regimens were adherent to guidelines, 89% of regimens were in the WHO 
AWaRe access category (Figure 1). Second regimens included more antibiotics from the watch/reserve 
categories and 71% of regimens were now in the access category. At discharge, 85% of regimens from 
the adherent group were in the access category.  Where initial antibiotic regimens were non-adherent 
to guidelines, only 49% of the regimens were in the access category. This increased to 61% for the 
second regimen and then again to 74% at discharge.  
 




The majority (83.6%) of antibiotic prescriptions were initiated in the emergency room, ranging from 
64.8% of prescriptions for UTI to 96.8% for sepsis (Table 3). Initiating antibiotic therapy at the ward 
increased the likelihood for non-adherence to guidelines, compared to prescribing in the emergency 
room, with an odds-ratio (OR) of 1.7, 95% CI (1.24, 2.36) (Table 4). When compared to LRTI, all groups 
of diagnoses were associated with a higher likelihood of non-adherence, ranging from OR = 1.42, 95% 
CI (1.03, 1.98) for COPD ex to OR =1.62, 95% CI (1.09, 2.41) for UTI (all p<0.05). Being admitted to 
hospital B was associated with reduced OR of non-adherence compared to hospital A, with an OR=0.63, 
95% CI (0.46, 0.86), p=0.004. Patients admitted from an institution had increased risk of receiving non-
adherent antibiotic treatment, OR=1.44, 95% CI (1.04, 2.00), p=0.029. Other factors tested were not 







Modification of antibiotic therapy 
The initial antibiotic regimen was modified during admission for 61.4% of the patients, and 20.6% of 
initial regimens was continued until discharge and then changed (Table 3). For the remaining patients, 
the initial antibiotic regimen was either stopped (9.7%) or continued after discharge (8.3%). This 
pattern varied between diagnoses. For patients with sepsis, 82.7% of initial antibiotic regimens were 
changed during admission, in contrast to 54.7% and 50.3% of regimens for SSTI and UTI patients, 
respectively.  
 
De-escalation was the most frequent first modification of antibiotic regimens and in total, 56.4% of 
first modifications were de-escalations, across all diagnoses (Table 3). For patients whose therapy was 
modified, the mean day of change was 3.6 days with 95% CI (3.5, 3.8). The time from start of antibiotic 
therapy to first change varied from patients with sepsis where day 3.0 with 95% CI (2.7, 3.3) was the 
mean day of change to patients with LRTI where change occurred on day 4.0 with 95% CI (3.7, 4.2).  
 
In total, 84.5% of patients received oral antibiotics during the course of treatment (Table 3). Time to 
oral treatment differed substantially between diagnoses, from 2.7 days, 95% CI (2.3, 3.1) for UTI’s to 
5.1 days, 95% CI (4.6, 5.5) for sepsis.  
 
Duration of antibiotic therapy 
The mean duration (in-house and post-discharge) of antibiotic therapy was 10.6 days, 95% CI (10.3, 
10.9) (Table 3).  Mean days of in-house and post-discharge therapy was similar across all diagnosis. 
Patients diagnosed with sepsis had the highest mean number of in-house antibiotic days at 6.6 days, 
95% CI (6.1, 7.1), while patients with SSTI had the highest mean days of therapy after discharge and 
total days of antibiotics with 7.1 , 95% CI (6.4, 7.7) and 12.5 days 95% CI (11.6, 13.4), respectively. After 





This study has identified key gaps and potential targets in the antibiotic prescribing process in hospitals 
for antibiotic stewardship interventions:   
Table 5: Identified gaps and potential targets for antibiotic stewardship interventions 
Gaps identified Potential targets 
Guideline adherence increased the use of narrow 
spectrum WHO Access group antibiotics in this study 
setting  
 
Promoting adherence to guidelines when prescribing 
empirical antibiotic therapy 
Antibiotic therapy was initiated in the emergency 
room for 83.6% of patients 
 
Targeting antibiotic prescribing in the emergency 
room, focusing on first line clinical staff 
Non-adherence to antibiotic guideline was 
associated with admittance from another institution 
Understanding the drivers for non-adherence in 
patients admitted from institutions and focusing on 
antibiotic prescribing for this group of patients 
 
Non-adherence to antibiotic guideline was 
associated with  the place of initiation of therapy, 
both regarding hospital site and wards compared to 
emergency room 
 
Understanding the cultural and contextual drivers for 
antibiotic prescribing across institutions and 
specialties 
Mean length of antibiotic therapy was similar across 
very different groups of diagnosis.   
 
Antibiotics prescribed upon discharge contributed 
significantly to the total days of antibiotic therapy 
and the appropriateness of this practice is often not 
clear 
 
Focusing on reducing the duration of antibiotic 
therapy safely, in accordance with emerging 
evidence on duration of antibiotic treatment  
 
One of the main aims of antibiotic stewardship programs is to reduce unnecessary use of broad-
spectrum antibiotics. We applied WHO AWaRe categories to describe the categories of antibiotics 
prescribed and found that when initial antibiotic treatment were according to Norwegian national 
guidelines, the majority of regimens (89%) consisted of only access group antibiotics. Non-adherent 
empirical regimens however, included several antibiotics from the watch/reserve category, but these 
regimens were often switched to regimens within the access categories upon first modification of 
treatment. At discharge, a greater number of regimens were from the access category, both suggestive 
11 
 
of clinical microsystems that tried to adhere to guidelines and antibiotic stewardship principles, but 
also likely related to the restricted availability of oral broad-spectrum antibiotics in Norway.  
 
In an American study from 2014, Braykov et al ranked antibiotics in categories of narrow-spectrum, 
broad-spectum, extended spectrum and restricted antibiotics [16]. Although there are some 
differences between the studies regarding the categories used to classify antibiotics, the results show 
that the prescription pattern is very different between the hospitals in the two studies. While 74% of 
patients in our study initially received antibiotics belonging only to the access group, most patients 
(78%) had broad-spectrum and extended spectrum antibiotics prescribed as empirical therapy in the 
Braykov-study. This reflects the nature of the Norwegian national antibiotic guidelines, which mainly 
have antibiotics from the access group as first-line empirical treatment recommendations.   
 
Initiating empirical antibiotic therapy is a crucial step in the treatment of infections and an important 
target for antibiotic stewardship interventions, as recently outlined by Tamma et al in their paper 
describing the four moments of antibiotic decision making [17]. In our study, antibiotics were mainly 
prescribed in the emergency departments. The physicians responsible for prescribing are usually  
interns and residents and in Norwegian hospitals, junior doctors rely heavily on guidelines for antibiotic 
prescribing [18]. From a separate study by Skodvin et al, including patients from the same intervention 
study cohort, we also know that mean compliance with guidelines recommendations for microbiology 
testing practices was 89% [19]. Most patients (83.6%) started antibiotic treatment in the emergency 
departments and non-adherence to guidelines was higher when treatment was initiated at the wards, 
compared to the emergency departments (OR=1.7, 95% CI (1.24-2.36), p=0.001). Other studies report 
reluctance from other medical teams to change therapy further down the line and together this 
highlights the need to focus on first-line clinical staff when planning antibiotic stewardship 




Non-adherence to guidelines was also associated with hospital site and whether patients were 
admitted from an institution or not. Patients admitted from nursing homes or other institutions may 
have had treatment prior to hospital admission. A combination of age, frailty, comorbidity and 
increased fear of resistant bacteria as cause of infection could have caused physicians to prescribe 
more broad-spectrum antibiotics for these patients. There is however, a need for a more thorough 
understanding of prescribing practices in this particular group of patients. Studies show that 
organisational culture influence antibiotic prescribing [20-22]. This could potentially explain why the 
odds ratio for non-adherent prescribing was significantly lower at hospital B than the two other 
included hospitals (OR=0.63 95% CI (0.46, 0.86), p=0.004). It also signals that a thorough understanding 
of organisational culture with barriers and facilitators for prudent antibiotic prescribing is an important 
part of planning for antibiotic stewardship interventions.  
 
Empirical antibiotic regimens were usually modified during admission (61.5%) and oral antibiotics were 
prescribed for 84.5% of patients. Other studies looking at the process of antibiotic prescribing in 
hospitals have focused on review of empirical therapy in relation to patient outcome or effect of 
interventions on prescribing process measures [23-25]. Braykov et al found that by the 5th day of 
therapy, 21,5% of empirical antibiotics were narrowed or discontinued, while Aillet et al found that 
antibiotic review was performed in 69% of patients with bacteraemia [16, 24].  In comparison, although 
we did not measure all patients at one specific day, 74,5% of empirical antibiotics were de-escalated 
(56,4%) and stopped (18,1%) as first modification of therapy in our study. Modifications happened 
between day 3 and 4 when initiation of therapy was defined as day 1. This is in agreement with 
recommendations stating that review of therapy should take place 48-72 hours after initiation of 
antibiotic therapy [26-28]. Upon discharge, 77.4% of patients continued antibiotic treatment and the 
mean length of post-discharge therapy was similar to the mean length of in-house treatment. This 
could mean either that most patients were not fully recovered upon discharge or that antibiotics were 
continued “just in case,” justifying an earlier discharge and giving the physician reassurance for the 
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patients’ well-being. The lack of documentation regarding length of antibiotic therapy has been heavily 
debated and studies suggest shorter antibiotic courses are safe and effective for an increasing number 
of diagnoses [29-33]. In our study, there was a remarkable similarity in duration of antibiotic therapy 
between the various groups of diagnoses, both in-hospital and post-discharge. For all patients, the 
mean number of days of antibiotic therapy were 10.6 days and the range for the various groups were 
narrow (9.3 to 12.5 days) when post-discharge therapy was included. There is a need for more studies, 
informing policymakers and clinicians about the optimal duration of antibiotic therapy for individual 
diagnosis, both in-hospital and for post-discharge use.  
 
This study has some limitations. When assessing adherence to guidelines on initiation of treatment, 
we used the indication for treatment stated in the electronic medical record, and this was usually a 
working diagnosis on admission. The diagnosis may change with more data and results available. To 
check whether this constituted a major issue for interpretation of data, we looked at the coherence 
between indication for treatment and the infection discharge diagnosis (if present) in the discharge 
letter. The group of diagnoses for which this might be an issue, is sepsis, where accuracy between 
indication for treatment and discharge diagnosis was low. During the study period, SIRS-criteria were 
used to screen patients for sepsis. SIRS identify more patients as suspected sepsis than the qSOFA 
score, which is currently in use. The low accuracy in this group could be due to lack of documentation 
of sepsis at discharge, with only the original focus of the infection often documented in discharge 
papers. It is possible that review of therapy took place without modifications to the patient’s antibiotic 
regimen. Such reviews were not identified during data collection and represents a limitation to this 
study.  We also did not take dosing into consideration when assessing adherence to guidelines and 
modification of therapy.  Appropriateness of antibiotic therapy was not evaluated after initial 
assessment of adherence to guidelines for empirical antibiotic treatment. It is therefore unknown 
whether escalation, de-escalation, stop or change was the best option for each individual patient. From 
the study by Skodvin et al, with patients derived from the same intervention study cohort, we do 
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however know that only 18% of patients had applicable microbiology test results and for only half of 
these patients (9% of the total cohort), these findings were used to guide therapy [19]. 
 
The Nordic countries and the Netherlands are currently in a more favourable position regarding 
antimicrobial resistance and are still able to utilize the most ecologically friendly antibiotics in empirical 
regimens. Exploring different ways of aggregating and analysing data to understand hospital antibiotic 
prescribing processes are however important in all countries and institutions, aiming to identify targets 
for stewardship interventions.  
 
Future studies should include assessment of appropriateness of therapy throughout the hospital stay 
to have a more comprehensive review of prescribing quality at every step of the process. Identifying 
and studying contributions from other healthcare professionals, like nurses and pharmacist and the 
team effort in antibiotic stewardship would also be valuable. As patient involvement and 
empowerment is increasing, the contribution of patients in antibiotic stewardship in hospital settings 
should also be investigated. Such studies could contribute to the identification of more targets for 
antibiotic stewardship interventions.   
 
Conclusions 
Analysis of patient level antibiotic prescribing and the use of WHO AWaRe to categorise antibiotic 
regimens throughout the hospital stay, identified relevant targets for antibiotic stewardship 
interventions in our population of hospital inpatients.  Identified targets included 1) adherence to 
guidelines 2) focus on prescribing physicians in the emergency room 3) prescribing for patients 
admitted from an institution 4) organisational culture and 5) duration of antibiotic therapy.  
 




AWaRe: Access, Watch, Reserve  
CCI: Charlson Comorbidity Index 
COPD ex: Exacerbation of Chronic Obstructive Pulmonary Disease 
eGFR: estimated Glomerular Filtration Rate 
UTI: Urinary Tract Infection 
LRTI: Lower Respiratory Tract Infection 
SIRS: Systemic Inflammatory Response Syndrome 
SSTI: Skin- and Soft Tissue Infections 
qSOFA: quick Sequential [Sepsis-related] Organ Failure Assessment score 
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Sex       
   Male 196 (47.6) 149 (53.2) 148 (59.7) 101 (67.3) 62 (42.8) 656 (53.1) 
   Female 216 (52.4) 131 (46.8) 100 (40.3) 49 (32.7) 83 (57.2) 579 (46.9) 
       
Agegroup       
   <= 45 43 (10.4) 2 (0.7) 51 (20.6) 52 (34.7) 16 (11.0) 164 (13.3) 
   46-65 88 (23.4) 70 (25.0) 50 (20.2) 48 (32.0) 21 (14.5) 277 (22.4) 
   66-85 192 (46.6) 179 (63.9) 106 (42.7) 37 (24.7) 71 (49.0) 585 (47.4) 
   >85 89 (21.6) 29 (10.4) 41 (16.4) 13 (8.7) 37 (25.5) 209 (16.9) 
       
Charlson Comorbidity 
Index 
      
       
   CCI = 0 163 (39.6) 8 (2.9) 111 (44.8) 108 (72.0) 72 (49.7) 462 (37.4) 
   CCI = 1  109 (26.5 ) 178 (63.6) 73 (29.4) 23 (15.3) 37 (25.5) 420 (34.0) 
   CCI = 2 58 (14.1) 47 (16.8) 41 (16.5) 9 (6.0) 21 (14.5) 176 (14.3) 
   CCI = 3 32 (7.8) 24 (8.6) 9 (3.6) 5 (3.3) 9 (6.2) 79 (6.4) 
   CCI = 4 14 (3.4) 18 (6.4) 6 (2.4) 3 (2.0) 1 (0.7) 42 (3.4) 
   CCI > 4 36 (8.7) 5 (1.8) 8 (3.2) 2 (1.3) 5 (3.5) 56 (4.5) 
       
       
Admitted from 
institution 
      
   No 341 (82.8) 255 (91.1) 203 (81.9) 141 (94.0) 115 (79.3) 1055 (85.4) 
   Yes 71 (17.2) 25 (8.9) 45 (18.1) 9 (6.0) 30 (20.7) 180 (14.6) 
       
       
AB allergies       
   Yes 43 (10.5) 38 (13.6) 19 (7.7) 13 (8.7) 9 (6.2) 122 (9.9) 
   No 367 (89.3) 
1 missing 
242 (86.4) 229 (92.3) 137 (91.3) 136 (93.8) 1111 (90.0) 
1 missing 
       
eGFR on admission       
   >50 308 (74.8) 230 (82.1) 187 (75.4) 129 (86.0) 101 (69.7) 955 (77.3) 
   10-50 103 (25.0) 49 (17.5) 59 (23.8) 21 (14.0) 43 (29.7) 275 (22.3) 
   <10 1 (0.24) 0 (0.0) 2 (0.8) 0 (0.0) 1 (0.7) 4 (0.32) 
   Dialysis 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.08) 
       
30-day mortality 55 (13.4) 19 (6.8) 22 (8.9) 2 (1.3) 6 (4.1) 104 (8.4) 
       
30-day readmission 78 (18.9) 76 (27.1) 39 (15.7) 26 (17.3) 37 (25.5) 256 (20.7) 
       










Figure 1: Antibiotic regimens prescribed from admission to discharge, by AWaRe categories and 





















































AB initiated       
  Emergency room 320 (77.7) 244 (87.1) 240 (96.8) 135 (90.0) 94 (64.8) 1033 (83.6) 
  Ward 92 (22.3) 36 (12.9) 8 (3.2) 15 (10.0) 51 (35.2) 202 (16.4) 
       
Adherence to guideline       
   Yes 280 (68.0) 177 (63.2) 151 (60.9) 90 (60.0) 80 (55.2) 778 (63.0) 
   No 132 (32.0) 103 (36.8) 97 (39.1) 60 (40.0) 65 (44.8) 457 (37.0) 
       
Accuracy between indication 
for AB-treatment and 
discharge infection 
diagnoses⌂ 
      
   Yes 331 (80.3) 255 (91.1) 103 (41.5) 143 (95.3) 122 (84.1) 954 (77.3) 
   No 81 (19.7) 25 (8.9) 145 (58.5) 7 (4.7) 23 (15.9) 281 (22.8) 
       
Empirical AB regimen was       
   Changed during admission 232 (56.3) 167 (59.6) 205 (82.7) 82 (54.7) 73 (50.3) 759 (61.4) 
   Changed at discharge 99 (24.0) 57 (20.4) 22 (8.9) 57 (38.0) 19 (13.1) 254 (20.6) 
   Continued at discharge 32 (7.8) 29 (10.4) 2 (0.8) 5 (3.3) 34 (23.5) 102 (8.3) 
   Stopped  49 (11.9) 27 (9.6) 19 (7.7) 6 (4.0) 19 (13.1) 120 (9.7) 
       
Empirical AB regimen was       
   Deescalated 227 (55.1) 176 (62.9) 142 (57.3) 95 (63.3) 56 (38.6) 696 (56.4) 
   Escalated 84 (20.4) 45 (16.1) 43 (17.3) 29 (19.3) 24 (16.5) 225 (18.2) 
   Changed – equal spectrum 19 (4.6) 3 (1.1) 41 (16.5) 15 (10.0) 12 (8.3) 90 (7.3) 
   Unchanged● 82 (19.9) 56 (20.0) 22 (8.9) 11 (7.3) 53 (36.6) 224 (18.1) 
       
Time to change of first AB 
regimen (n=1011) 
      
   Mean  (95% CI)* 4.0 (3.7, 4.2) 3.9 (3.7, 4.1) 3.0 (2.7, 3.3) 3.4 (3.1, 3.8) 3.5 (3.1, 3.9) 3.6 (3.5, 3.8) 
       
Number of treatment 
regimens through admission 
      
   1 41 (9.9) 33 (11.8) 5 (2.0) 6 (4.0) 34 (23.5) 119 (9.6) 
   2 245 (59.5) 187 (66.8) 86 (34.7) 77 (51.3) 75 (51.7) 670 (54.3) 
   3 92 (22.3) 43 (15.4) 122 (49.2) 44 (29.3) 29 (20.0) 330 (26.7) 
   >3 34 (8.3) 17 (6.1) 35 (14.1) 23 (15.3) 7 (4.8) 116 (9.4) 
       
Oral AB given       
   Yes 326 (79.1) 243 (86.8) 204 (82.3) 136 (90.7) 135 (93.1) 1044 (84.5) 
   No 86 (20.9) 37 (13.2) 44 (17.7) 14 (9.3) 10 (6.9) 191 (15.5) 
   Mean first day  (95% CI) 4.2 (3.9, 4.5) 3.6 (3.3, 3.8) 5.1 (4.6, 5.5) 4.8 (4.3, 5.3) 2.7 (2.3, 3.1) 4.1 (3.9, 4.3) 
       
First change of AB regimen       
   During admission 232 (56.3) 167 (59.6) 205 (82.7) 82 (54.7) 73 (50.3) 759 (61.5) 
   At discharge 99 (24.0) 57 (20.4) 22 (8.9) 57 (38.0) 19 (13.1) 254 (20.6) 
   Continued at discharge 32 (7.8) 29 (10.4) 2 (0.8) 5 (3.3) 34 (23.5) 102 (8.3) 
   Stopped 49 (11.9) 27 (9.6) 19 (7.7) 6 (4.0) 19 (13.1) 120 (9.7) 
       
Antibiotics prescribed at 
discharge 
      
   Yes 296 (71.8) 214 (76.4) 193 (77.8) 139 (92.7) 114 (78.6) 956 (77.4) 
   No 116 (28.2) 66 (23.6) 55 (22.2) 11 (7.3) 31 (21.4) 279 (22.6) 
       
Days of AB treatment       
   Mean (95% CI)∆ 10.2 (9.7, 10.6) 10.0 (9.6, 10.5) 11.5 (10.8, 12.2) 12.5 (11.6, 13.4) 9.3 (8.6, 10.1) 10.6 (10.3, 10.9) 
   In-hospital 6.3 (5.9, 6.7) 6.0 (5.7, 6.4) 6.6 (6.1, 7.1) 6.0 (5.3, 6.6) 5.3 (4.8, 5.8) 6.2 (5.9, 6.4) 
   After discharge▪ 5.5 (5.2, 5.8) 5.2 (4.9, 5.6) 6.3 (5.8, 6.8) 7.1 (6.4, 7.7) 4.9 (4.5, 5.3) 5.8 (5.6, 6.0) 
24 
 
*Does not include patients who did not change initial antibiotic regimen (stop was only change)  
⌂ Measured as match between initial grouped indication for treatment and grouped discharge diagnosis  
● Unchanged includes patients where discontinuation of antibiotics was the only change  
∆ Does not include 40 patients where length of prescription treatment after discharge was not stated in discharge letter.  
▪ Does not include 40 patients where length of prescripton treatment after discharge was not stated in discharge letter and 







































OR (95% CI) 
p-value Adjusted analysis* 
OR (95% CI) 
p-value 
AB initiated       
  Emergency room 670 (64.9) 363 (35.1) 1  1  
  Ward 108 (53.5) 94 (46.5) 1.6 (1.18, 2.18) 0.002 1.7 (1.24, 2.36) 0.001 
       
Indication for treatment       
   LRTI 280 (68.0) 132 (32.0) 1   1  
   COPD ex 177 (63.2) 103 (36.8) 1.23 (0.90, 1.70) 0.196 1.42 (1.03, 1.98) 0.035 
   Sepsis 151 (60.9) 97 (39.1) 1.36 (0.98, 1.89) 0.065 1.44 (1.02, 2.02) 0.037 
   SSTI 90 (60.0) 60 (40.0) 1.41 (0.96, 2.10) 0.079 1.56 (1.05, 2.31) 0.028 
   UTI 80 (55.2) 65 (44.8) 1.72 (1.17, 2.54) 0.006 1.62 (1.09, 2.41) 0.017 
       
Hospital       
   Hospital A 376 (60.8) 242 (39.2) 1  1  
   Hospital B 203 (70.7) 84 (29.3) 0.64 (0.48, 0.87) 0.004 0.63 (0.46, 0.86) 0.004 
   Hospital C 199 (60.3) 131 (39.7) 1.02 (0.78, 1.34) 0.872 0.95 (0.71, 1.26) 0.712 
       
Admitted from institution       
    No 678 (64.3) 377 (35.7) 1    
    Yes 100 (55.6) 80 (44.4) 1.44 (1.04, 1.98) 0.026 1.44 (1.04, 2.00) 0.029 
       
Accuracy between 
indication for AB-treatment and 
discharge infection diagnoses⌂ 
      
   Yes 604 (63.3) 350 (36.7) 1  1  
   No 174 (61.9) 107 (38.1) 1.06 (0.81, 1.40) 0.671 0.99 (0.72, 1.35) 0.936 
       
Sex       
   Male  411 (62.7) 245 (37.3) 1  1  
   Female 367 (63.4) 212 (36.6) 0.97 (0.77. 1.22) 0.790 0.98 (0.77, 1.24) 0.857 
       
Agegroup       
   <45 106 (64.6) 58 (35.4) 1  1  
   46-65 168 (60.7) 109 (39.3) 1.19 (0.79, 1.77) 0.405 1.26 (0.83, 1.91) 0.277 
   66-85 367 (62.7) 218 (37.3) 1.09 (0.76, 1.56) 0.656 1.08 (0.73, 1.60) 0.695 
   >85 137 (65.6) 72 (34.4) 0.96 (0.63, 1.47) 0.854 0.87 (0.54, 1.37) 0.540 
       
Charlson Comorbidity Index       
   CCI=0 304 (65.8) 158 (34.2) 1  1  
   CCI=1 265 (63.1) 155 (36.9) 1.13 (0.85, 1.48) 0.402 1.14 (0.83, 1.56) 0.421 
   CCI=2 102 (57.9) 74 (42.1) 1.40 (0.98, 1.99) 0.066 1.35 (0.93, 1.97) 0.115 
   CCI=3 48 (60.8) 31 (39.2) 1.24 (0.76, 2.10) 0.386 1.20 (0.72, 2.02) 0.482 
   CCI=4 26 (61.9) 16 (38.1) 1.18 (0.62, 2.27) 0.611 1.18 (0.60, 2.33) 0.626 
   CCI>4 33 (58.9) 23 (41.1) 1.34 (0.76, 2.36) 0.310 1.39 (0.77, 2.51) 0.279 
       
Multiple working diagnoses       
   1 493 (64.6) 270 (35.4) 1  1  
   2 238 (60.7) 154 (39.3) 1.18 (0.92, 1.52) 0.193 1.12 (0.87, 1.46) 0.381 
   3 47 (58.8) 33 (41.2) 1.28 (0.80, 2.05) 0.299 1.18 (0.73, 1.92) 0.491 
       
Antibiotic allergies◊       
   No 708 (63.7) 403 (36.3) 1  1  
   Yes 69 (56.6) 53 (43.4) 1.35 (0.92, 1.97) 0.120 1.40 (0.95, 2.06) 0.088 
       
eGFR       
   eGFR >50 598 (62.6) 357 (37.4) 1  1  




* All factors are adjusted for where AB was initiated, indication for AB treatment, hospital and admittance from institution 
⌂ Measured as match between initial grouped indication for treatment and grouped discharge diagnosis  



















































Table 1: Grouping of indication for treatment 
 Indication for treatment*  
Lower respiratory 
tract infections (LRTI) 
Community acquired pneumonia (normal and severe), healthcare 
associated pneumonia (normal and severe), unspecified lower respiratory 
tract infections, unknown – suspected pneumonia, aspiration pneumonia, 







Patients with COPD, presenting with LRTI (community and healthcare 
associated). 
Sepsis Suspected cases of sepsis originating from; lower respiratory tract, urinary 
tract, unknown focus, soft tissue, abdomen and catheter.  
 
Skin and soft tissue 
infections (SSTI) 
 
Erysipelas, cellulitis, abscess, other skin and soft tissue infections, mastitis, 
necrotising soft tissue infections, postoperative wound infection. 
Urinary tract 
infections (UTI) 
UTI – unspecified, pyelonephritis, lower UTI/cystitis, unknown-suspected 
UTI, catheter associated UTI.  
 














Overview of AWaRe categories with study modifications 
AWaRe 
Category 
AWaRe antibiotic Active substances Study antibiotics 
added to category 
Access* Beta-lactam antibiotics 
 
Amoxicillin, amoxicillin + clavulanic acid, 
ampicillin, benzathine benzylpenicillin, 
benzylpenicillin, cefalexin, cefazolin, 
cloxacillin, phenoxymetylpenicillin,  





 Other antibiotics amikacin, chloramphenicol, clindamycin, 
doxycycline, gentamicin, metronidazole, 





Watch Quinolones and 
fluoroquinolones  
e.g. Ciprofloxacin, levofloxacin, 
moxifloxacin, norfloxacin 
 
   2nd gen 
cephalosporins: 
Cefuroxime 
 3rd generation 
cephalosporins (with or 
without beta-lactamase 
inhibitor)  
e.g. Cefixime, ceftriaxone, cefotaxime, 
ceftazidime 
 
 Macrolides  e.g. Azithromycin, clarithromycin, 
erythromycin 
 




e.g. piperacillin - tazobactam  
 Carbapenems e.g. meropenem, imipenem + cilastatin  
 Penems e.g. faropenem  
Reserve Aztreonam   
 4th generation 
cephalosporins 
e.g. cefepime  
 5th generation 
cephalosporins 
e.g. ceftaroline  
 Polymyxins  e.g. polymyxin B, colistin  
 Oxazolidinones  e.g. linezolid  
 Fosfomycin (IV)   
 Tigecyclin   
 Daptomycin   
* Antibiotics included in the access category only 
 
 
Table 3: Evaluation of antimicrobial spectrum and categorization of change 
ESCALATION Added spectrum in new regime 
Cipro →Ampi/genta Gram positives (Enterococci) 
Erytro→ Ceriaxon Gram negatives 
Cefotax→ Pip-taz Anaerobes, enterococci 
Ampi/genta→ Pip-taz Anaerobes 
Pc iv →TXS Gram neg 
Ampi→Doxy Atypicals (Intracellular) 
Pc→Clinda Anaerobes and staphylococci 
Genta→TXS Streptococci 
Cefotax→ Cipro/Metron Anaerobes 
Cefurox→Cefotax Gram negatives 
Pip-taz→Meropenems ESBLs 
Pc/Azitro→Cefotax Gram negatives 
Cefotaxime/Metron→Merop ESBLs 
Kloxa→Pc/Clinda Anaerobes 
Cefurox→ Pip-taz Anaerobes, enterococci 
Fenoxypc→Claritromycin Atypicals (Intracellular) 
Kloxa→Pc/Metro Anaerobes 
Cefotax/Metron→Meropenems ESBLs 
Pc/metro→Pc/genta Gram negatives 
Cefotaxime/Ampi→PipTazo Anarobes 
Pc→Doxy Atypicals (Intracellular) 
Cefurox→ TXS Gram negatives 
Cipro/genta→ TXS Gram positives 
Vanco/Clinda→ TXS Gram negatives 
  
DE- ESCALATION Reduced spectrum in new regime 
Pc/genta→Ampi Gram negatives 
Ampi/genta→ Cefuroxime Enterococci, some gram negatives 
Pip-taz→ Fenoxypc+cipro Anaerobes 
Cefotax→ Cipro Gram positives 
Clinda →Dicloxa Anaerobes and ↓streptocci 
Cefotaxime/Metron→Cipro/TXS Anaerobes 
Pip-taz→Cipro Anaerobes and gram positives 
Pc/genta→ Fenoxypc Gram negatives, S aureus 
Pc/genta→Amoxi  S aureus, Several gram negs 
Cefurox→Cipro Gram positives 
TXS→Mecillinam Gram positives, Several gram negs 




Pc/genta→Pc/metro Gram negatives 
Kloxa /Clinda→Pc S aureus, some anaerobes 
Cefurox→Cipro Gram positives 
Ampi/genta→Amoxi S aureus, Several gram negs 
PipTaz→Cipro/Azitro Anaerobes,  enterococci 
Ampi/genta→TXS Enterococci 
Kloxa/genta→Cipro Gram positives 
Pc/Kloxa→Fenoxypc S aureus 
Pc/genta→Fenoxypc Gram neg, S aureus 
Pc/genta/metro→Cipro/metro Gram positives 
Amoxi/Pivmecill→Cipro Gram positives, enterococci 
Ampi/genta→Cipro Gram positives, incl enterococci 
  
UNCHANGED  
Cefotax↔ Pc/genta  
Cefotax↔TXS  
Pc/Cipro ↔ Pc/genta  
Ampi/genta↔ Ceftriaxon/Pc  
Pc/Cefotax↔Cefotax  
Pc/Clinda/genta↔ Clinda/genta  
Ampi/genta/Cefurox↔ Ampi/genta  
Cefotax /genta↔Cefotax  











Forskrivning og oppfølging av antibiotika i sykehus 
 
Seksjon 1. GENERELLE OPPLYSNINGER 
 
Del 1.1. Personen som registrerer  
Navn ☐ Lars Kåre Kleppe 
☐ Ingrid Smith 
☐ Marion Neteland 
☐ Jannicke Slettli Wathne 
☐ Trude Cecilie Mellingsæter 
☐ Brita Skodvin 
☐ Ottar Hope 
☐ Eli Hoem 
☐ Torbjørn Smith 
☐ Dagfinn Lunde Markussen 
☐ Per Espen Akselsen 
☐ Torhild Vedeler 
Dato   
   
Del 1.2. HF, sykehus, avdeling, post (navn) 
☐ 11: SUS - Infeksjon 
☐ 12: SUS - Gastro 
☐ 13: SUS - Lunge 
 
☐ 21: HDS - Infeksjon 
☐ 22: HDS - Gastro 
☐ 23: HDS – Lunge 
 
☐ 31: HUS – Infeksjon (Med 6) 
☐ 32: HUS – Infeksjon (Med 5 V) 
☐ 33: HUS – Gastro (Med 1 V) 
☐ 34: HUS – Lunge post 1 
☐ 35: HUS – Lunge post 3 
 
Seksjon 2. PASIENT        
Del 2.1. Pasientdata  
Fødselsdato:   Kjønn:                                        ☐Mann  ☐ Kvinne 
Studie ID-nr:  NPR-ID:  
Inndato:  Utdato:  
Relevante allergier 
mot antibiotika?  
☐Ja    ☐Nei     Ja - beskriv:  
 
Innlagt institusjon siste 
48 timer 
(pleiepersonell 24/7)                         
☐ Ja   ☐Nei Utskrevet til  
institusjon           
☐ Ja  ☐Nei ☐ Ikke rel. 
Død under aktuell 
innleggelse: 
☐Ja    ☐Nei  Død innen 30 dager 
etter utskrivning 
☐Ja   ☐Nei ☐ Ikke rel. 
Reinlagt innen 30 
dager etter utskrivning 








Forskrivning og oppfølging av antibiotika i sykehus 
 Del 2.2 Komorbiditet: 
☐ Kreft ☐Hjertesvikt ☐ Diabetes ☐ Nyresvikt ☐ Apopleksi ☐Rusmisbruk ☐ Annet:  ☐ KOLS 
 
Del 2.3. Indikasjon for antibiotikabehandling (TD=Tentativ diagnose, ED =Endelig diagnose) 





Generell diagnose Spesifikk diagnose 
  ☐Annet (ingen infeksjon) – beskriv:  
  ☐ CNS Infeksjon                          ☐ Hjerneabscess    ☐ Meningitt    
  ☐ Endokarditt                              ☐ Nativ klaff ☐ Biologisk klaff ☐ Mekanisk klaff 
  ☐ Abdominal infeksjon              ☐ Gastroenteritt                        
☐ Clost. difficile  
☐ Intraabd. Abscess                 
☐ Peritonitt  
  




      cholangitt        
  ☐ Gynekologisk infeksjon           
  ☐ Hud- og bløtdelsinfeksjon     ☐ Erysipelas                     
☐ Cellulitt     
☐ Nekrot. fascitt    
☐ Postop. sårinfeksjon           
☐ Mastitt                        
☐ Abscess                                  
☐ Annet – beskriv* 
 
  ☐ Infeksjon uten kjent fokus     Evt. hva mistenkes? 
☐ Pneumoni    ☐  UVI      ☐ Abdominal infeksjon                  
  ☐ Infiserte intravasale katetre   
  ☐ Neutropen feber                     ☐ Samfunnservervet    
☐ Nosokomial      
Utgangspkt^: 
 
  ☐ Ortopediske infeksjoner       ☐ Proteseinfeksjon 
      (eksklusjon!)        
☐ Osteomyelitt 
☐   Artritt  
  ☐ Nedreluftveisinfeksjon (NLI) 
 
☐ Konfus ☐ Resp. >30  ☐ Age>65    
☐ BT syst < 90 el. diast. < 65mmHg          
☐ Pneumoni                                    
      ☐ Samf. ervervet 
     ☐ Nosokomial        
     ☐ Aspirasjon 
     ☐ Atypisk 
☐ Uspesifisert  NLI 
☐ KOLS eksaserbasj. 
☐   Bronkitt   
☐   Lungeabscess   
☐ Empyem     
☐ CRB-65 score 3-4 
el. behandlingssvikt 
 
  ☐ Sepsis                                         ☐ Samf.ervervet                     Utgangspkt^: 
☐ Nosokomial    
  ☐ Urinveisinfeksjoner (UVI)       ☐ Kateterass. UVI           
☐ Pyelonefritt  
☐ Nedre UVI/ cystitt 
☐ Uspesifisert 
  ☐ Øvre luftveisinfeksjon (ØLI)   ☐   Sinusitt / otitt  
☐   Tonsilitt                        
☐ Uspesifisert     














































































































































































































































































































































2.5  Labprøver Kommentar: 
Nyrefunksjon ☐ GFR >50      ☐ GFR 10-50    ☐ GFR <10        ☐ Dialyse       
2.5 Mikrobe Materiale (til dyrkning) 















1 Prøve tatt – ingen vekst          
2 Prøve tatt - normalflora          
3 Prøve tatt – ÷ klinisk bet.          
4 Acinetobacter           
5 Chlamydia trach.          
6 Clostridium diff.          
7 E. coli          
8 Enterobacteriacae -          
9 Enterokokker (gr D)          
10 H.influenzae          
11 H.pylori          
12 Klebsiella          
13 MRSA          
14 Mycoplasma pn.          
15 Proteus          
16 Pseudomonas          
17 S. gr A          
18 S. gr B          
19 S. gr G          
20 S. pneumoniae          
21 S.gr C          
22 Staph. aur          
23 Staph. KNS          
24 Annet:          
Kommentar:  
 
2.6 Mikrobe                                       Test (antigentest, mikroskopering osv) 
L-PCR Bordetella pertussis ☐Pos            ☐Neg          Annet Pneumokokk antigen ☐Pos            ☐Neg           
Bordetella parapertussis ☐Pos            ☐Neg          Legionella pneumophilia ☐Pos            ☐Neg           
Mycoplasma pneum. ☐Pos            ☐Neg          Clostridium difficile toxin ☐Pos            ☐Neg           
Chlamydophilia pneum. ☐Pos            ☐Neg          VRE – screening ☐Pos            ☐Neg           
Influensavirus A ☐Pos            ☐Neg          Mycobacterium tuberculosis ☐Pos            ☐Neg           
Influensavirus B ☐Pos            ☐Neg          Mycoplasma pneum. antistf ☐Pos            ☐Neg           
Humant metapneu. virus ☐Pos            ☐Neg          Borrelia antistoff ☐Pos            ☐Neg           
Parainfluensavirus 1-2-3 ☐Pos            ☐Neg            
Annet funn/kommentar:    
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